Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Nelle 24 ore
Buona
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Eccellente
Maggiore
Nelle 24 ore
Buona
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Non specificato
Discreta
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Buona
Maggiore
Nelle 24 ore
Buona
Maggiore
Non specificato
Buona
Maggiore
Ritardato
Eccellente
Maggiore
Non specificato
Buona
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin
exposure and increased risk of myopathy, including rhabdomyolysis.
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN
CONVERTING ENZYME INHIBITORS may result in hyperkalemia.
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and
ANGIOTENSIN II RECEPTOR BLOCKERS may result in increased risk of adverse events
(ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive
respiratory depression.
Concurrent use of AMIODARONE and BETA-ADRENERGIC BLOCKERS may result in
hypotension, bradycardia, or cardiac arrest.
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an
increased risk of bleeding.
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in
changes in blood glucose and increased risk of hypoglycemia or hyperglycemia.
Concurrent use of BETA-ADRENERGIC BLOCKERS and BETA-2 AGONISTS may result
in decreased effectiveness of either the beta-adrenergic blocker and/or the beta-2 agonist.
Concurrent use of PAROXETINE and ANTIPLATELET AGENTS may result in an increased
risk of bleeding.
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and
NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in an increased risk of
bleeding.
Concurrent use of SERTRALINE and ANTIPLATELET AGENTS may result in an increased
risk of bleeding.
Concurrent use of CITALOPRAM and ANTIPLATELET AGENTS may result in an increased
risk of bleeding.
Concurrent use of AMIODARONE and CALCIUM CHANNEL BLOCKERS may result in
bradycardia, atrioventricular block and/or sinus arrest.
Concurrent use of SOTALOL and DIURETICS may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of AMIODARONE and WARFARIN may result in an increased risk of
bleeding.
Concurrent use of LOW MOLECULAR WEIGHT HEPARINS and NONSTEROIDAL
ANTIINFLAMMATORY AGENTS may result in an increased risk of bleeding.
Numero:
Assistiti:
22.084
4.519
16.960
3.290
16.693
3.716
16.523
2.541
12.409
2.402
11.573
3.575
9.662
4.285
9.039
3.060
8.895
2.388
8.539
4.106
8.095
2.015
7.415
1.783
7.326
1.306
6.948
1.312
6.838
2.007
6.525
3.063
Pag. 1 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Maggiore
Maggiore
Non specificato
Ritardato
Ritardato
Discreta
Eccellente
Eccellente
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Ritardato
Eccellente
Maggiore
Nelle 24 ore
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Maggiore
Non specificato
Non specificato
Buona
Discreta
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Ritardato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Eccellente
Maggiore
Non specificato
Discreta
Concurrent use of ENOXAPARIN and WARFARIN may result in increased risk of bleeding.
Concurrent use of ASPIRIN and WARFARIN may result in an increased risk of bleeding.
Concurrent use of SIMVASTATIN and WARFARIN may result in increased risk of bleeding
and an increased risk of rhabdomyolysis.
Concurrent use of VENLAFAXINE and ANTIPLATELET AGENTS may result in an
increased risk of bleeding.
Concurrent use of FORMOTEROL and QT PROLONGING DRUGS may result in increased
risk of ventricular arrhythmias.
Concurrent use of ESCITALOPRAM and ANTIPLATELET AGENTS may result in an
increased risk of bleeding.
Concurrent use of DIGITALIS GLYCOSIDES and THIAZIDE DIURETICS may result in
digitalis toxicity (nausea, vomiting, arrhythmias).
Concurrent use of ALLOPURINOL and ENALAPRIL may result in hypersensitivity reactions
(Stevens-Johnson syndrome, skin eruptions, anaphylactic coronary spasm).
Concurrent use of LEVOFLOXACIN and SALMETEROL may result in an increased risk of
QT interval prolongation.
Concurrent use of CITALOPRAM and LANSOPRAZOLE may result in increased citalopram
exposure and risk of QT interval prolongation.
Concurrent use of DULOXETINE and ANTIPLATELET AGENTS may result in an increased
risk of bleeding.
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
Concurrent use of CITALOPRAM and PANTOPRAZOLE may result in increased citalopram
exposure and risk of QT interval prolongation.
Concurrent use of AMIODARONE and SIMVASTATIN may result in increased exposure to
simvastatin and an increased risk of myopathy or rhabdomyolysis.
Concurrent use of FLECAINIDE and HYDROCHLOROTHIAZIDE may result in increased
risk of electrolyte imbalance and subsequent cardiotoxicity.
Concurrent use of TICLOPIDINE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS
may result in increased risk of gastrointestinal bleeding.
Concurrent use of AMLODIPINE and CLOPIDOGREL may result in decreased antiplatelet
effect and increased risk of thrombotic events.
Concurrent use of ASPIRIN and KETOPROFEN may result in increased risk of serious
gastrointestinal adverse effects (ulceration, bleeding, perforation).
Numero:
Assistiti:
6.309
6.248
5.932
2.825
2.049
1.703
5.826
821
5.634
3.001
5.610
1.436
5.227
1.173
5.220
1.326
5.049
2.861
4.529
824
4.470
890
4.305
4.152
1.062
831
4.074
868
3.610
467
3.312
1.323
3.142
896
3.136
1.868
Pag. 2 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Eccellente
Maggiore
Maggiore
Ritardato
Non specificato
Buona
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Concurrent use of SIMVASTATIN and VERAPAMIL may result in increased exposure to
simvastatin and an increased risk of myopathy or rhabdomyolysis.
Concurrent use of PAROXETINE and ANTICOAGULANTS may result in an increased risk
of bleeding.
Concurrent use of QUETIAPINE and TRAZODONE may result in an increased risk of QT
interval prolongation.
Concurrent use of DIGOXIN and SPIRONOLACTONE may result in digoxin toxicity
(nausea, vomiting, cardiac arrhythmias).
Concurrent use of TICLOPIDINE and ANTICOAGULANTS may result in an increased risk
of bleeding.
Concurrent use of CITALOPRAM and OMEPRAZOLE may result in increased citalopram
exposure and risk of QT interval prolongation.
Concurrent use of SERTRALINE and ANTICOAGULANTS may result in an increased risk
of bleeding.
Concurrent use of ATORVASTATIN and VERAPAMIL may result in increased exposure to
atorvastatin and an increased risk of myopathy or rhabdomyolysis.
Concurrent use of CLARITHROMYCIN and LEVOFLOXACIN may result in an increased
risk of QT interval prolongation.
Concurrent use of LAMOTRIGINE and VALPROIC ACID may result in increased
elimination half-life of lamotrigine leading to lamotrigine toxicity (fatigue, drowsiness, ataxia)
and an increased risk of life-threatening rashes.
Concurrent use of POTASSIUM and RAMIPRIL may result in hyperkalemia.
Concurrent use of CLARITHROMYCIN and FLUTICASONE may result in increased
fluticasone plasma concentration and reduced plasma cortisol concentration.
Concurrent use of AZITHROMYCIN and LEVOFLOXACIN may result in an increased risk
of QT interval prolongation.
Concurrent use of CITALOPRAM and ANTICOAGULANTS may result in an increased risk
of bleeding.
Concurrent use of CITALOPRAM and ESOMEPRAZOLE may result in increased
citalopram exposure and increased risk of QT interval prolongation.
Concurrent use of LEVOFLOXACIN and CLASS III ANTIARRHYTHMIC AGENTS may
result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
Numero:
Assistiti:
2.983
556
2.676
909
2.494
493
2.491
493
2.475
906
2.449
485
2.441
760
2.339
414
2.330
1.825
2.263
180
2.248
2.187
658
1.617
2.144
1.673
2.130
641
2.117
490
2.105
1.100
Pag. 3 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Ritardato
Eccellente
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Concurrent use of LEVOFLOXACIN and WARFARIN may result in an increased risk of
bleeding.
Concurrent use of FLUCONAZOLE and LEVOFLOXACIN may result in an increased risk of
QTc prolongation and torsades de pointes.
Concurrent use of BISOPROLOL and CLONIDINE may result in increased risk of sinus
bradycardia; exaggerated clonidine withdrawal response (acute hypertension).
Concurrent use of AZITHROMYCIN and SALMETEROL may result in an increased risk of
QT interval prolongation.
Concurrent use of KETOROLAC and NONSTEROIDAL ANTIINFLAMMATORY AGENTS
may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal
bleeding and/or perforation).
Concurrent use of OPIOID ANALGESICS and OPIOID AGONISTS/ANTAGONISTS may
result in precipitation of withdrawal symptoms (abdominal cramps, nausea, vomiting,
lacrimation, rhinorrhea, anxiety, restlessness, elevation of temperature or piloerection).
Concurrent use of CLARITHROMYCIN and SALMETEROL may result in increased plasma
concentration of salmeterol.
Concurrent use of CITALOPRAM and QUETIAPINE may result in increased risk of QT
interval prolongation.
Concurrent use of OPIOID ANALGESICS and BENZODIAZEPINES may result in additive
respiratory depression.
Concurrent use of DIGOXIN and VERAPAMIL may result in increased serum digoxin
concentrations and risk of digitalis toxicity.
Concurrent use of CLOPIDOGREL and OMEPRAZOLE may result in reduction in clinical
efficacy of clopidogrel and increased risk for thrombosis.
Concurrent use of ESCITALOPRAM and ANTICOAGULANTS may result in an increased
risk of bleeding.
Concurrent use of AZITHROMYCIN and SIMVASTATIN may result in an increased risk of
rhabdomyolysis.
Concurrent use of AZITHROMYCIN and CLARITHROMYCIN may result in an increased
risk of QT interval prolongation.
Concurrent use of HEPARIN and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may
result in increased risk of gastrointestinal bleeding.
Concurrent use of VERAPAMIL and BETA-ADRENERGIC BLOCKERS may result in
hypotension, bradycardia.
ControindicatoNelle 24 ore
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Ritardato
Eccellente
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Nelle 24 ore
Buona
Numero:
Assistiti:
1.948
1.277
1.888
930
1.783
266
1.778
1.157
1.643
934
1.603
337
1.547
1.110
1.488
319
1.483
228
1.481
264
1.423
329
1.385
490
1.336
987
1.336
1.184
1.336
686
1.328
371
Pag. 4 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Discreta
Concurrent use of AMIODARONE and SALMETEROL may result in an increased risk of
QT interval prolongation.
Concurrent use of CLARITHROMYCIN and SIMVASTATIN may result in an increased risk
of myopathy or rhabdomyolysis.
Concurrent use of CLOPIDOGREL and ESOMEPRAZOLE may result in reduction in
clinical efficacy of clopidogrel and increased risk for thrombosis.
Concurrent use of CLONIDINE and NEBIVOLOL may result in increased risk of sinus
bradycardia; exaggerated clonidine withdrawal response (acute hypertension).
Concurrent use of ASPIRIN and HEPARIN may result in an increased risk of bleeding.
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and SELECTIVE
SEROTONIN REUPTAKE INHIBITORS may result in increased risk of serotonin syndrome
(hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of LITHIUM and DOPAMINE-2 ANTAGONISTS may result in weakness,
dyskinesias, increased extrapyramidal symptoms, encephalopathy, and brain damage.
Concurrent use of CLOPIDOGREL and ANTICOAGULANTS may result in an increased
risk of bleeding.
Concurrent use of ALFUZOSIN and LEVOFLOXACIN may result in an increased risk of QT
interval prolongation.
Concurrent use of DIGOXIN and AMIODARONE may result in digoxin toxicity (nausea,
vomiting, cardiac arrhythmias).
Concurrent use of PAROXETINE and TRAMADOL may result in an increased risk of
seizures and serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status
changes); a decrease in the analgesic effect of tramadol.
Concurrent use of TORSEMIDE and WARFARIN may result in increased warfarin plasma
concentrations, decreased warfarin clearance, and elevated INR.
Concurrent use of PRIMIDONE and CYP3A4 SUBSTRATES may result in decreased
exposure of CYP3A4 substrates.
Concurrent use of ENALAPRIL and POTASSIUM may result in hyperkalemia.
Concurrent use of ATENOLOL and CLONIDINE may result in increased risk of sinus
bradycardia; exaggerated clonidine withdrawal response (acute hypertension).
Concurrent use of CITALOPRAM and TRAMADOL may result in an increased risk of
seizures and serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status
changes).
ControindicatoNon specificato
Buona
Maggiore
Ritardato
Eccellente
Maggiore
Non specificato
Discreta
Maggiore
Maggiore
Nelle 24 ore
Non specificato
Eccellente
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Eccellente
Maggiore
Nelle 24 ore
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Maggiore
Ritardato
Non specificato
Buona
Discreta
Maggiore
Nelle 24 ore
Discreta
Numero:
Assistiti:
1.279
329
1.275
971
1.268
305
1.251
212
1.225
1.217
641
764
1.170
222
1.135
454
1.132
664
1.131
298
1.131
384
1.074
232
1.073
86
1.061
1.056
290
217
1.037
282
Pag. 5 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Nelle 24 ore
Discreta
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Buona
Concurrent use of ATORVASTATIN and CLARITHROMYCIN may result in increased
atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis.
Concurrent use of CLASS I ANTIARRHYTHMIC AGENTS and CLASS III
ANTIARRHYTHMIC AGENTS may result in an increased risk of cardiotoxicity (QT
prolongation, torsades de pointes, cardiac arrest).
Concurrent use of AMITRIPTYLINE and TRAMADOL may result in an increased risk of
seizures; increased concentrations of tramadol and decreased concentrations of tramadol
active metabolite, M1.
Concurrent use of TRAMADOL and VENLAFAXINE may result in an increased risk of
serotonin syndrome.
Concurrent use of MIRTAZAPINE and VENLAFAXINE may result in an increased risk of
serotonin syndrome.
Concurrent use of METOCLOPRAMIDE and ANTIPSYCHOTICS may result in an
increased risk of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of TAMSULOSIN and STRONG CYP3A4 INHIBITORS may result in
increased tamsulosin exposure.
Concurrent use of KETOROLAC and ANTICONVULSANTS may result in reduced
anticonvulsant effectiveness.
Concurrent use of DICUMAROL and ASPIRIN may result in an increased risk of bleeding.
Concurrent use of SERTRALINE and TRAMADOL may result in an increased risk of
seizures and serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status
changes).
Concurrent use of LEVOFLOXACIN and QUETIAPINE may result in an increased risk of
QT prolongation.
Concurrent use of TRAMADOL and TRAZODONE may result in increased risk of serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of ASPIRIN and KETOROLAC may result in enhanced gastrointestinal
adverse effects (peptic ulcers, gastrointestinal bleeding, and/or perforation) and possible
increase in serum ketorolac levels.
Concurrent use of VENLAFAXINE and ANTICOAGULANTS may result in an increased risk
of bleeding.
Concurrent use of DULOXETINE and TRAMADOL may result in an increased risk of
serotonin syndrome.
ControindicatoNon specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Maggiore
Ritardato
Nelle 24 ore
Buona
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
ControindicatoNon specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Numero:
Assistiti:
1.024
762
1.009
278
991
373
983
178
972
174
950
257
937
554
925
402
907
904
250
291
884
432
879
199
862
546
859
161
859
190
Pag. 6 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Nelle 24 ore
Eccellente
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Buona
Maggiore
Nelle 24 ore
Discreta
Maggiore
Non specificato
Buona
Maggiore
Maggiore
Ritardato
Ritardato
Eccellente
Buona
Maggiore
Ritardato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Discreta
Concurrent use of CITALOPRAM and TRAZODONE may result in an increased risk of QT
interval prolongation and serotonin syndrome (hypertension, hyperthermia, myoclonus,
mental status changes).
Concurrent use of BARBITURATES and BENZODIAZEPINES may result in additive
respiratory depression.
Concurrent use of CITALOPRAM and LEVOFLOXACIN may result in increased risk of QT
interval prolongation.
Concurrent use of FENTANYL and FLUCONAZOLE may result in increased or prolonged
opioid effects (CNS depression, respiratory depression).
Concurrent use of CLARITHROMYCIN and ROSUVASTATIN may result in increased risk
of rhabdomyolysis.
Concurrent use of COTRIMOXAZOLE and FLUCONAZOLE may result in an increased risk
of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of AMOXICILLIN and WARFARIN may result in an increased risk of
bleeding.
Concurrent use of TRAMADOL and ESCITALOPRAM may result in an increased risk of
seizures and serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status
changes).
Concurrent use of CLOPIDOGREL and NONSTEROIDAL ANTIINFLAMMATORY AGENTS
may result in an increased risk of bleeding.
Concurrent use of LISINOPRIL and POTASSIUM may result in hyperkalemia.
Concurrent use of OXYCODONE and SERTRALINE may result in an increased risk of
serotonin syndrome (tachycardia, hyperthermia, myoclonus, mental status changes).
Concurrent use of THEOPHYLLINE and LEVOFLOXACIN may result in theophylline
toxicity (nausea, vomiting, palpitations, seizures).
Concurrent use of LEVOFLOXACIN and TRAZODONE may result in an increased risk of
QT interval prolongation.
Concurrent use of ALFUZOSIN and SALMETEROL may result in an increased risk of QT
interval prolongation.
Concurrent use of FENOFIBRATE and SIMVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of FENOFIBRATE and ROSUVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Numero:
Assistiti:
858
207
846
63
843
520
814
203
810
588
809
299
793
570
776
232
755
397
738
729
208
142
728
335
722
376
698
190
697
215
682
181
Pag. 7 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Ritardato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Maggiore
Non specificato
Non specificato
Discreta
Buona
Maggiore
Non specificato
Buona
Maggiore
Nelle 24 ore
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Nelle 24 ore
Buona
Maggiore
Nelle 24 ore
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Concurrent use of HEPARIN and NITROGLYCERIN may result in a decrease in partial
thromboplastin time.
Concurrent use of AZITHROMYCIN and FLUCONAZOLE may result in an increased risk of
QT interval prolongation.
Concurrent use of QUETIAPINE and GLUCOCORTICOIDS may result in decreased serum
quetiapine concentrations.
Concurrent use of RIZATRIPTAN and SELECTIVE SEROTONIN REUPTAKE INHIBITORS
may result in an increased risk of serotonin syndrome.
Concurrent use of LEVOFLOXACIN and PROPAFENONE may result in increased risk of
QT interval prolongation.
Concurrent use of ENOXAPARIN and HEPARIN may result in increased risk of bleeding.
Concurrent use of FENTANYL and PAROXETINE may result in increased risk of serotonin
syndrome or neuroleptic malignant syndrome-like reactions.
Concurrent use of OPIOID ANALGESICS and BARBITURATES may result in additive
respiratory depression.
Concurrent use of VENLAFAXINE and TRICYCLIC ANTIDEPRESSANTS may result in an
increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) and
adverse effects of both drugs.
Concurrent use of FENTANYL and SERTRALINE may result in increased risk of serotonin
syndrome or neuroleptic malignant syndrome-like reactions.
Concurrent use of ANTIPSYCHOTICS and PHENOTHIAZINES may result in an increased
risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of FENTANYL and TRAZODONE may result in increased risk of serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of CITALOPRAM and FENTANYL may result in increased risk of serotonin
syndrome.
Concurrent use of ACARBOSE and GLYBURIDE may result in an increased risk of
hypoglycemia.
Concurrent use of CLONIDINE and VERAPAMIL may result in increased incidence of sinus
bradycardia.
Concurrent use of CITALOPRAM and SALMETEROL may result in an increased risk of QT
interval prolongation.
Concurrent use of ASPIRIN and NAPROXEN may result in increased risk of serious
gastrointestinal adverse effects (ulceration, bleeding, perforation).
Numero:
Assistiti:
678
168
673
490
670
233
670
159
659
277
647
645
375
118
634
126
634
154
626
110
616
143
610
106
606
103
572
97
563
67
562
185
561
286
Pag. 8 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Eccellente
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Eccellente
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
ControindicatoNon specificato
Discreta
Maggiore
Non specificato
Discreta
Maggiore
Maggiore
Nelle 24 ore
Ritardato
Buona
Discreta
Maggiore
Nelle 24 ore
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Buona
Concurrent use of AZITHROMYCIN and CLASS III ANTIARRHYTHMIC AGENTS may
result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
Concurrent use of RANOLAZINE and SIMVASTATIN may result in increased simvastatin
exposure and increased risk of rhabdomyolysis.
Concurrent use of AMITRIPTYLINE and FENTANYL may result in an increased risk of
serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of HYDROCHLOROTHIAZIDE and LITHIUM may result in increased
lithium concentrations and lithium toxicity (weakness, tremor, excessive thirst, confusion).
Concurrent use of ATORVASTATIN and FENOFIBRATE may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of CLOPIDOGREL and NIFEDIPINE may result in decreased antiplatelet
effect and increased risk of thrombotic events.
Concurrent use of ESCITALOPRAM and TRAZODONE may result in increased risk of
serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of PROPAFENONE and SALMETEROL may result in increased risk of QT
interval prolongation.
Concurrent use of FLUCONAZOLE and SALMETEROL may result in an increased risk of
QT interval prolongation.
Concurrent use of SERTRALINE and TRAZODONE may result in increased risk of
serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of FENTANYL and NIFEDIPINE may result in severe hypotension.
Concurrent use of CLARITHROMYCIN and NIFEDIPINE may result in inhibition of
nifedipine metabolism resulting in an increase in nifedipine concentrations and an
increased risk of hypotension and/or bradycardia.
Concurrent use of AMIODARONE and FENTANYL may result in cardiac toxicity (low
cardiac output) and an increased risk of fentanyl toxicity (CNS depression, respiratory
depression).
Concurrent use of CLARITHROMYCIN and FLUCONAZOLE may result in an increased
risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of FLECAINIDE and LEVOFLOXACIN may result in an increased risk of
QT interval prolongation.
Concurrent use of SIMVASTATIN and FLUCONAZOLE may result in an increased risk of
myopathy or rhabdomyolysis.
Numero:
Assistiti:
555
327
545
142
534
139
526
86
510
170
505
144
489
119
485
89
481
251
480
144
478
471
58
256
463
86
461
362
457
184
455
258
Pag. 9 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Severità:
Insorgenza:
Documentazione:
Descrizione:
Maggiore
Non specificato
Buona
Maggiore
Maggiore
Ritardato
Non specificato
Buona
Discreta
Maggiore
Maggiore
Ritardato
Nelle 24 ore
Discreta
Discreta
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Non specificato
Discreta
Concurrent use of QUETIAPINE and HALOPERIDOL may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of POTASSIUM and AMILORIDE may result in hyperkalemia.
Concurrent use of CLARITHROMYCIN and CLASS III ANTIARRHYTHMIC AGENTS may
result in increased risk of QT interval prolongation and torsade de pointes.
Concurrent use of PERINDOPRIL and POTASSIUM may result in hyperkalemia.
Concurrent use of AMIODARONE and QUETIAPINE may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of DULOXETINE and PAROXETINE may result in increased duloxetine
serum concentrations and an increased risk of serotonin syndrome.
Concurrent use of DULOXETINE and TRAZODONE may result in increased risk of
serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of AMITRIPTYLINE and LEVOFLOXACIN may result in an increased risk
of QT interval prolongation.
Concurrent use of ALISKIREN and VALSARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ESCITALOPRAM and OXYCODONE may result in an increased risk of
serotonin syndrome (tachycardia, hyperthermia, myoclonus, mental status changes).
Concurrent use of AZITHROMYCIN and WARFARIN may result in an increased risk of
bleeding.
Concurrent use of CARBAMAZEPINE and NIFEDIPINE may result in decreased nifedipine
exposure.
Concurrent use of CEFIXIME and WARFARIN may result in an increased risk of bleeding.
Concurrent use of QUETIAPINE and SALMETEROL may result in an increased risk of QT
interval prolongation.
Concurrent use of AZATHIOPRINE and RAMIPRIL may result in myelosuppression.
Concurrent use of AMIODARONE and TRAZODONE may result in increased risk of QT
interval prolongation and torsade de pointes.
Concurrent use of CYCLOSPORINE and EVEROLIMUS may result in an increased risk of
everolimus toxicity.
Concurrent use of MORPHINE and PHENOTHIAZINES may result in an increase in central
nervous system and respiratory depression.
Concurrent use of ALLOPURINOL and CAPTOPRIL may result in hypersensitivity reactions
(Stevens-Johnson syndrome, skin eruptions).
ControindicatoNon specificato
Buona
Maggiore
Ritardato
Buona
Maggiore
Ritardato
Buona
ControindicatoRitardato
Discreta
Maggiore
Maggiore
Non specificato
Non specificato
Buona
Discreta
Maggiore
Maggiore
Ritardato
Ritardato
Discreta
Buona
Maggiore
Non specificato
Buona
Maggiore
Non specificato
Discreta
Maggiore
Ritardato
Buona
Numero:
Assistiti:
453
139
449
448
177
295
447
446
150
92
444
172
444
77
444
278
443
99
443
113
439
325
438
40
437
436
310
91
436
436
86
109
435
37
432
147
423
124
Pag. 10 di 55
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Nelle 24 ore
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Ritardato
Discreta
Controindicato Non specificato
Buona
Controindicato Ritardato
Buona
Controindicato Ritardato
Discreta
Controindicato Ritardato
Eccellente
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Buona
Controindicato Non specificato
Buona
Controindicato Non specificato
Eccellente
Controindicato Ritardato
Buona
Concurrent use of KETOROLAC and NONSTEROIDAL ANTIINFLAMMATORY AGENTS
may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal
bleeding and/or perforation).
Concurrent use of CLARITHROMYCIN and SIMVASTATIN may result in an increased risk
of myopathy or rhabdomyolysis.
Concurrent use of METOCLOPRAMIDE and ANTIPSYCHOTICS may result in an
increased risk of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of ASPIRIN and KETOROLAC may result in enhanced gastrointestinal
adverse effects (peptic ulcers, gastrointestinal bleeding, and/or perforation) and possible
increase in serum ketorolac levels.
Concurrent use of FLUCONAZOLE and SALMETEROL may result in an increased risk of
QT interval prolongation.
Concurrent use of ALISKIREN and VALSARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of CARBAMAZEPINE and NIFEDIPINE may result in decreased nifedipine
exposure.
Concurrent use of ALISKIREN and RAMIPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of SELEGILINE and LEVODOPA may result in hypertension or increased
mortality.
Concurrent use of NIFEDIPINE and PHENOBARBITAL may result in decreased nifedipine
exposure.
Concurrent use of SIMVASTATIN and CYCLOSPORINE may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of FROVATRIPTAN and RIZATRIPTAN may result in prolonged
vasospastic reactions.
Concurrent use of ALISKIREN and IRBESARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ALISKIREN and TELMISARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ITRACONAZOLE and SIMVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of CITALOPRAM and FLUCONAZOLE may result in increased risk of QT
interval prolongation and serotonin syndrome.
Numero:
Assistiti:
1.643
934
1.275
971
950
257
862
546
481
251
443
99
438
40
362
66
292
58
273
40
251
36
230
77
210
56
208
44
203
113
202
114
Pag. 1 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Buona
Controindicato Ritardato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Concurrent use of FLUCONAZOLE and ONDANSETRON may result in an increased risk
of QT interval prolongation.
Concurrent use of ALMOTRIPTAN and RIZATRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of FLUCONAZOLE and QUETIAPINE may result in increased quetiapine
serum concentrations and an increased risk of QT prolongation .
Concurrent use of ALISKIREN and OLMESARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ALISKIREN and LOSARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of GEMFIBROZIL and SIMVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of ALMOTRIPTAN and ELETRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of ELETRIPTAN and RIZATRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of METOCLOPRAMIDE and PAROXETINE may result in an increased risk
of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of ALFUZOSIN and FLUCONAZOLE may result in an increased risk of
torsade de pointes.
Concurrent use of METOCLOPRAMIDE and TRICYCLIC ANTIDEPRESSANTS may result
in an increased risk of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of ALMOTRIPTAN and FROVATRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of FLUCONAZOLE and GRANISETRON may result in an increased risk of
QT interval prolongation.
Concurrent use of ALISKIREN and ENALAPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ALISKIREN and CANDESARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of METOCLOPRAMIDE and TRAZODONE may result in an increased risk
of extrapyramidal reactions.
Concurrent use of CITALOPRAM and METOCLOPRAMIDE may result in an increased risk
of extrapyramidal reactions or neuroleptic malignant syndrome.
Numero:
Assistiti:
195
89
190
55
149
69
138
43
137
32
121
43
117
30
111
36
108
76
102
46
97
46
91
37
89
64
83
20
78
16
74
47
70
42
Pag. 2 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Ritardato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Buona
Controindicato Nelle 24 ore
Buona
Controindicato Nelle 24 ore
Discreta
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Controindicato Nelle 24 ore
Discreta
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Discreta
Concurrent use of DULOXETINE and RASAGILINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of VENLAFAXINE and METOCLOPRAMIDE may result in an increased
risk of developing extrapyramidal symptoms or neuroleptic malignant syndrome.
Concurrent use of TAMOXIFEN and WARFARIN may result in an increased risk of
bleeding.
Concurrent use of DIHYDROERGOTAMINE and ELETRIPTAN may result in increased risk
of prolonged vasospastic reactions.
Concurrent use of ALISKIREN and LISINOPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of SELEGILINE and VENLAFAXINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of PAROXETINE and RASAGILINE may result in serotonin syndrome
(labile blood pressure, hyperthermia, neuromuscular abnormalities, mental status changes,
gastrointestinal symptoms).
Concurrent use of FROVATRIPTAN and ELETRIPTAN may result in prolonged vasospastic
reactions.
Concurrent use of RIZATRIPTAN and ERGOT DERIVATIVES may result in prolonged
vasospastic reactions.
Concurrent use of RASAGILINE and TRAMADOL may result in coma, severe hypertension
or hypotension, severe respiratory depression, convulsions, malignant hyperpyrexia,
excitation, peripheral vascular collapse, death.
Concurrent use of SELEGILINE and SERTRALINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of RIZATRIPTAN and SUMATRIPTAN may result in prolonged vasospastic
reactions.
Concurrent use of PIMOZIDE and TRICYCLIC ANTIDEPRESSANTS may result in an
increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of ZOLMITRIPTAN and RIZATRIPTAN may result in prolonged vasospastic
reactions.
Concurrent use of FROVATRIPTAN and ZOLMITRIPTAN may result in prolonged
vasospastic reactions.
Concurrent use of CLARITHROMYCIN and LOVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Numero:
Assistiti:
64
11
62
23
62
17
62
8
61
10
61
12
59
14
59
29
53
13
50
16
49
13
47
12
47
3
47
14
47
17
47
37
Pag. 3 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Eccellente
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Controindicato Nelle 24 ore
Discreta
Controindicato Nelle 24 ore
Discreta
Concurrent use of GEMFIBROZIL and REPAGLINIDE may result in increased plasma
concentrations of repaglinide.
Concurrent use of TRAZODONE and MONOAMINE OXIDASE INHIBITORS may result in
an increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental
status changes).
Concurrent use of ESCITALOPRAM and SELEGILINE may result in an increased risk of
serotonin syndrome (labile blood pressure, hyperthermia, neuromuscular abnormalities,
mental status changes, gastrointestinal symptoms) .
Concurrent use of ALMOTRIPTAN and ZOLMITRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of ALMOTRIPTAN and SUMATRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of DULOXETINE and METOCLOPRAMIDE may result in an increased risk
of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of ESCITALOPRAM and METOCLOPRAMIDE may result in an increased
risk of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of ALISKIREN and PERINDOPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of HALOPERIDOL and PIMOZIDE may result in cardiotoxicity (QT
prolongation, torsades de pointes, cardiac arrest).
Concurrent use of CITALOPRAM and SELEGILINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of ALFUZOSIN and ITRACONAZOLE may result in an increase in alfuzosin
exposure.
Concurrent use of ALISKIREN and CAPTOPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ELETRIPTAN and ZOLMITRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of ITRACONAZOLE and PIMOZIDE may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of PAROXETINE and SELEGILINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of BIPERIDEN and POTASSIUM may result in risk of gastrointestinal
lesions.
Numero:
Assistiti:
38
8
37
13
35
10
33
16
31
4
29
25
28
24
28
7
28
3
27
8
25
12
24
4
23
12
23
1
22
7
21
11
Pag. 4 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Ritardato
Eccellente
20
16
Controindicato Non specificato
Buona
20
4
Controindicato Non specificato
Discreta
20
7
Controindicato Non specificato
Discreta
19
5
Controindicato Non specificato
Discreta
19
6
Controindicato Nelle 24 ore
Buona
17
5
Controindicato Nelle 24 ore
Discreta
14
3
Controindicato Non specificato
Discreta
Concurrent use of CLARITHROMYCIN and COLCHICINE may result in increased
colchicine plasma concentrations and increased risk of toxicity.
Concurrent use of ALISKIREN and QUINAPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ALMOTRIPTAN and DIHYDROERGOTAMINE may result in prolonged
vasospastic reactions.
Concurrent use of RANOLAZINE and TRICYCLIC ANTIDEPRESSANTS may result in
increased tricyclic antidepressant plasma concentrations.
Concurrent use of DULOXETINE and SELEGILINE may result in CNS toxicity or serotonin
syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of FROVATRIPTAN and SUMATRIPTAN may result in prolonged
vasospastic reactions.
Concurrent use of BUPROPION and SELEGILINE may result in serotonin syndrome
(hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of MIRTAZAPINE and SELEGILINE may result in CNS toxicity.
14
7
Controindicato Ritardato
Buona
14
4
Controindicato Non specificato
Discreta
13
9
Controindicato Non specificato
Discreta
13
5
Controindicato Ritardato
Buona
12
9
Controindicato Ritardato
Buona
12
6
Controindicato Nelle 24 ore
Discreta
12
5
Controindicato Non specificato
Discreta
12
1
Controindicato Non specificato
Discreta
Concurrent use of RIFAMPIN and NIFEDIPINE may result in decreased nifedipine
effectiveness.
Concurrent use of CLARITHROMYCIN and RANOLAZINE may result in an increase in
ranolazine steady state plasma concentrations and an increased risk of cardiotoxicity ( QT
prolongation, torsades de pointes, cardiac arrest).
Concurrent use of MIRTAZAPINE and RASAGILINE may result in hypertensive crisis,
circulatory collapse, CNS toxicity.
Concurrent use of ERGOT DERIVATIVES and MACROLIDE ANTIBIOTICS may result in
an increased risk of acute ergotism (nausea, vomiting, vasospastic ischemia).
Concurrent use of ITRACONAZOLE and LOVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of SELEGILINE and TRAMADOL may result in nausea, vomiting,
cardiovascular collapse, respiratory depression, seizures or serotonin syndrome
(hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of ESCITALOPRAM and PIMOZIDE may result in QTc interval prolongation
and an increased risk of torsade de pointes.
Concurrent use of PHENOBARBITAL and RANOLAZINE may result in decreased
ranolazine plasma concentrations.
11
2
Numero:
Assistiti:
Pag. 5 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Ritardato
Buona
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Controindicato Ritardato
Eccellente
Controindicato Ritardato
Discreta
Concurrent use of CLOZAPINE and FLUCONAZOLE may result in an increased risk of QT
interval prolongation and increased plasma concentrations of clozapine.
Concurrent use of CITALOPRAM and PIMOZIDE may result in an increased risk of torsade
de pointes.
Concurrent use of CARBAMAZEPINE and RANOLAZINE may result in decreased
ranolazine plasma concentrations.
Concurrent use of PIMOZIDE and QUETIAPINE may result in an increased risk of QT
prolongation.
Concurrent use of NIFEDIPINE and PHENYTOIN may result in decreased nifedipine
exposure and increased risk of phenytoin toxicity (ataxia, hyperreflexia, nystagmus, tremor)
.
Concurrent use of ITRACONAZOLE and RANOLAZINE may result in an increase in
ranolazine steady state plasma concentrations and an increased risk of cardiotoxicity ( QT
prolongation, torsades de pointes, cardiac arrest).
Concurrent use of TRIFLUOPERAZINE and VENLAFAXINE may result in an increased risk
of neuroleptic malignant syndrome and an increased risk of cardiotoxicity ( QT prolongation,
torsades de pointes, cardiac arrest).
Concurrent use of FELODIPINE and ITRACONAZOLE may result in increased felodipine
serum concentrations and potential cardiotoxicity.
Concurrent use of TRIAMTERENE and AMILORIDE may result in hyperkalemia.
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Concurrent use of PAROXETINE and PIMOZIDE may result in an increased risk of
pimozide toxicity including cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
Concurrent use of DANAZOL and SIMVASTATIN may result in an increased risk of
myopathy or rhabdomyolysis.
Concurrent use of METOCLOPRAMIDE and RIVASTIGMINE may result in increased risk
of extrapyramidal effects.
Concurrent use of METOCLOPRAMIDE and MIRTAZAPINE may result in an increased risk
of extrapyramidal reactions.
Concurrent use of PIMOZIDE and TETRABENAZINE may result in an increased risk of QT
interval prolongation.
Concurrent use of ZOLMITRIPTAN and SUMATRIPTAN may result in prolonged
vasospastic reactions.
Numero:
Assistiti:
11
5
11
6
11
2
10
3
9
3
9
4
9
1
8
6
8
2
8
4
8
1
7
6
7
6
7
3
7
4
Pag. 6 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Non specificato
Discreta
6
2
Controindicato Nelle 24 ore
Buona
6
6
Controindicato Non specificato
Discreta
6
3
Controindicato Non specificato
Discreta
6
2
Controindicato Non specificato
Discreta
5
5
Controindicato Non specificato
Discreta
5
2
Controindicato Non specificato
Discreta
5
3
Controindicato Non specificato
Discreta
5
1
Controindicato Ritardato
Discreta
Concurrent use of LEVOFLOXACIN and PIMOZIDE may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of FROVATRIPTAN and ERGOT DERIVATIVES may result in prolonged
vasospastic reactions.
Concurrent use of ALMOTRIPTAN and ERGOTAMINE may result in prolonged vasospastic
reactions.
Concurrent use of ELETRIPTAN and SUMATRIPTAN may result in an increased risk for
vasospastic reactions.
Concurrent use of COLCHICINE and ITRACONAZOLE may result in increased colchicine
plasma concentrations and increased risk of toxicity.
Concurrent use of CLOMIPRAMINE and MONOAMINE OXIDASE INHIBITORS may result
in an increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental
status changes).
Concurrent use of CITALOPRAM and ZIPRASIDONE may result in an increased risk of
torsade de pointes.
Concurrent use of CARBAMAZEPINE and MONOAMINE OXIDASE INHIBITORS may
result in an increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus,
mental status changes).
Concurrent use of TRIAMTERENE and SPIRONOLACTONE may result in hyperkalemia.
4
3
Controindicato Nelle 24 ore
Discreta
3
Controindicato Nelle 24 ore
Buona
4
2
Controindicato Non specificato
Buona
4
2
Controindicato Non specificato
Discreta
3
2
Controindicato Non specificato
Discreta
3
2
Controindicato Nelle 24 ore
Discreta
2
1
Controindicato Non specificato
Discreta
Concurrent use of AZITHROMYCIN and PIMOZIDE may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of PIMOZIDE and CLARITHROMYCIN may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of ALISKIREN and EPROSARTAN may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of MONOAMINE OXIDASE INHIBITORS and MONOAMINE OXIDASE
INHIBITORS may result in hypertensive crisis (headache, palpitation, neck stiffness) or
seizure.
Concurrent use of PIMOZIDE and SALMETEROL may result in an increased risk of QT
interval prolongation.
Concurrent use of POTASSIUM and TRIHEXYPHENIDYL may result in risk of
gastrointestinal lesions.
Concurrent use of BUPROPION and METOCLOPRAMIDE may result in an increased risk
of extrapyramidal reactions.
4
2
1
Numero:
Assistiti:
Pag. 7 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per Interazione
Assititi: tutti
Periodo :
Severità:
01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr.
Insorgenza:
Documentazione:
Descrizione:
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Non specificato
Discreta
Controindicato Nelle 24 ore
Buona
Controindicato Non specificato
Discreta
Controindicato Non specificato
Buona
Controindicato Nelle 24 ore
Eccellente
Controindicato Non specificato
Buona
Concurrent use of SIMVASTATIN and TELITHROMYCIN may result in increased risk of
myopathy or rhabdomyolysis.
Concurrent use of ALFUZOSIN and PIMOZIDE may result in an increased risk of QT
interval prolongation.
Concurrent use of NORFLOXACIN and PIMOZIDE may result in an increased risk of QT
interval prolongation.
Concurrent use of ALISKIREN and MOEXIPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Concurrent use of ZIPRASIDONE and PHENOTHIAZINES may result in an increased risk
of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of FLUVOXAMINE and METOCLOPRAMIDE may result in an increased
risk of extrapyramidal reactions or neuroleptic malignant syndrome.
Concurrent use of PIMOZIDE and RISPERIDONE may result in cardiotoxicity (QT
prolongation, torsades de pointes, cardiac arrest).
Concurrent use of PENTOXIFYLLINE and NONSTEROIDAL ANTIINFLAMMATORY
AGENTS may result in an increased risk of bleeding.
Concurrent use of OXCARBAZEPINE and SELEGILINE may result in an increase in
selegiline plasma concentration.
Concurrent use of ZOLMITRIPTAN and ERGOT DERIVATIVES may result in prolonged
vasospastic reactions.
Concurrent use of ZIPRASIDONE and FLUCONAZOLE may result in an increased risk of
cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest).
Concurrent use of RANOLAZINE and RIFAMPIN may result in decreased ranolazine
plasma concentrations.
Concurrent use of AMITRIPTYLINE and SELEGILINE may result in neurotoxicity, seizures,
or serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Concurrent use of ALISKIREN and BENAZEPRIL may result in an increased risk of
hyperkalemia, renal impairment, and hypotension.
Numero:
Assistiti:
2
1
2
1
2
1
2
1
2
1
2
1
2
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
Pag. 8 di 8
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
17,283
3.9%
3.468
4.4%
5.0
C08CA01-C10AA01 AMLODIPINA BESILATO-SIMVASTATINA
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including
rhabdomyolysis.
B01AC04-B01AC06 CLOPIDOGREL-ACIDO ACETILSALICILICO
11,557
2.6%
3.568
4.5%
3.2
1.8%
5.1
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an increased risk of bleeding.
C01BD01-C07AB07 AMIODARONE CLORIDRATO-BISOPROLOLO EMIFUMARATO7,361
1.7%
1.449
Concurrent use of AMIODARONE and BETA-ADRENERGIC BLOCKERS may result in hypotension, bradycardia, or cardiac arrest.
B01AC06-N06AB05 ACIDO ACETILSALICILICO-PAROXETINA CLORIDRATO
7,129
1.6%
2.037
2.6%
3.5
1.5%
2.007
2.5%
3.4
1.4%
1.713
2.2%
3.7
1.4%
2.825
3.6%
2.2
1.4%
2.047
2.6%
3.1
1.3%
1.510
1.9%
3.8
1.555
2.0%
3.5
Concurrent use of PAROXETINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
B01AA03-C01BD01 WARFARIN SODICO-AMIODARONE CLORIDRATO
6,838
Concurrent use of AMIODARONE and WARFARIN may result in an increased risk of bleeding.
B01AC06-N06AB06 ACIDO ACETILSALICILICO-SERTRALINA CLORIDRATO
6,398
Concurrent use of SERTRALINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
B01AA03-B01AB05 WARFARIN SODICO-ENOXAPARINA SODICA
6,309
Concurrent use of ENOXAPARIN and WARFARIN may result in increased risk of bleeding.
B01AA03-B01AC06 WARFARIN SODICO-ACIDO ACETILSALICILICO
6,244
Concurrent use of ASPIRIN and WARFARIN may result in an increased risk of bleeding.
B01AC06-N06AB04 ACIDO ACETILSALICILICO-CITALOPRAM BROMIDRATO
5,730
Concurrent use of CITALOPRAM and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
B01AA03-C10AA01 WARFARIN SODICO-SIMVASTATINA
5,403
1.2%
Concurrent use of SIMVASTATIN and WARFARIN may result in increased risk of bleeding and an increased risk of rhabdomyolysis.
4,885
1.1%PROPIONATO
2.770
J01MA12-R03AK06 LEVOFLOXACINA EMIIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
3.5%
1.8
1.1%
5.5
Concurrent use of LEVOFLOXACIN and SALMETEROL may result in an increased risk of QT interval prolongation.
C01BD01-C08CA01 AMIODARONE CLORIDRATO-AMLODIPINA BESILATO
4,713
1.1%
859
Concurrent use of AMIODARONE and CALCIUM CHANNEL BLOCKERS may result in bradycardia, atrioventricular block and/or sinus
arrest.
B01AC06-N06AX16 ACIDO ACETILSALICILICO-VENLAFAXINA CLORIDRATO
4,539
1.0%
695
0.9%
6.5
824
1.0%
5.5
Concurrent use of VENLAFAXINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
A02BC03-N06AB04 LANSOPRAZOLO-CITALOPRAM BROMIDRATO
4,529
1.0%
Concurrent use of CITALOPRAM and LANSOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
B01AC06-N06AB10 ACIDO ACETILSALICILICO-ESCITALOPRAM OSSALATO
4,460
1.0%
1.206
1.5%
3.7
Concurrent use of ESCITALOPRAM and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
1.0%
1.055
1.3%
4.1
4,152
0.9%
A02BC02-N06AB04 PANTOPRAZOLO SODICO SESQUIIDRATO-CITALOPRAM BROMIDRATO
831
1.0%
5.0
B01AC05-B01AC06 TICLOPIDINA CLORIDRATO-ACIDO ACETILSALICILICO
4,294
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
Concurrent use of CITALOPRAM and PANTOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
A10BA02-J01MA12 METFORMINA CLORIDRATO-LEVOFLOXACINA EMIIDRATO 4,059
0.9%
2.177
2.7%
1.9
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
C01BD01-C10AA01 AMIODARONE CLORIDRATO-SIMVASTATINA
3,686
0.8%
784
1.0%
4.7
Concurrent use of AMIODARONE and SIMVASTATIN may result in increased exposure to simvastatin and an increased risk of myopathy or
rhabdomyolysis.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
3,680
0.8%
947
1.2%
3.9
C09AA02-M04AA01 ENALAPRIL MALEATO-ALLOPURINOLO
Concurrent use of ALLOPURINOL and ENALAPRIL may result in hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions,
anaphylactic coronary spasm).
B01AC06-N06AX21 ACIDO ACETILSALICILICO-DULOXETINA CLORIDRATO
3,529
0.8%
753
0.9%
4.7
506
0.6%
6.5
Concurrent use of DULOXETINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
C01BD01-C07AG02 AMIODARONE CLORIDRATO-CARVEDILOLO
3,297
0.7%
Concurrent use of AMIODARONE and BETA-ADRENERGIC BLOCKERS may result in hypotension, bradycardia, or cardiac arrest.
B01AC06-M01AE03 ACIDO ACETILSALICILICO-KETOPROFENE
3,110
0.7%
1.850
2.3%
1.7
Concurrent use of ASPIRIN and KETOPROFEN may result in increased risk of serious gastrointestinal adverse effects (ulceration, bleeding,
perforation).
C08CA13-C10AA01 LERCANIDIPINA CLORIDRATO-SIMVASTATINA
3,048
0.7%
709
0.9%
4.3
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including
rhabdomyolysis.
B01AB05-M01AE01 ENOXAPARINA SODICA-IBUPROFENE
3,022
0.7%
1.564
2.0%
1.9
Concurrent use of LOW MOLECULAR WEIGHT HEPARINS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in an
increased risk of bleeding.
J01FA09-R03AK06
2,954
0.7%
CLARITROMICINA-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
1.070
1.3%
2.8
1.0%
3.6
Concurrent use of CLARITHROMYCIN and SALMETEROL may result in increased plasma concentration of salmeterol.
B01AC04-C08CA01 CLOPIDOGREL-AMLODIPINA BESILATO
2,858
0.6%
801
Concurrent use of AMLODIPINE and CLOPIDOGREL may result in decreased antiplatelet effect and increased risk of thrombotic events.
C03EA01-C09AA05 AMILORIDE CLORIDRATO/IDROCLOROTIAZIDE-RAMIPRIL 2,765
0.6%
673
0.8%
4.1
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
C08DA01-C10AA01 VERAPAMIL CLORIDRATO-SIMVASTATINA
2,763
0.6%
514
0.6%
5.4
Concurrent use of SIMVASTATIN and VERAPAMIL may result in increased exposure to simvastatin and an increased risk of myopathy or
rhabdomyolysis.
0.7%
4.9
2,614
0.6% PROPIONATO
694
0.9%
C07AB07-R03AK06 BISOPROLOLO EMIFUMARATO-SALMETEROLO XINAFOATO/FLUTICASONE
3.8
N02AA01-N02AB03 MORFINA CLORIDRATO-FENTANIL
2,747
0.6%
564
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
Concurrent use of BETA-ADRENERGIC BLOCKERS and BETA-2 AGONISTS may result in decreased effectiveness of either the
beta-adrenergic blocker and/or the beta-2 agonist.
N05AH04-N06AX05 QUETIAPINA FUMARATO-TRAZODONE CLORIDRATO
2,494
0.6%
493
0.6%
5.1
485
0.6%
5.0
Concurrent use of QUETIAPINE and TRAZODONE may result in an increased risk of QT interval prolongation.
A02BC01-N06AB04 OMEPRAZOLO-CITALOPRAM BROMIDRATO
2,449
0.6%
Concurrent use of CITALOPRAM and OMEPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
N02AA59-N02AB03 PARACETAMOLO/CODEINA FOSFATO-FENTANIL
2,438
0.5%
536
0.7%
4.5
0.5%
6.3
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
C03DA01-C09AA05 SPIRONOLATTONE-RAMIPRIL
2,432
0.5%
383
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
2,417
0.5%
1.577
2.0% DIIDRATO
1.5
J01MA12-R03AK07 LEVOFLOXACINA EMIIDRATO-BECLOMETASONE DIPROPRIONATO/FORMOTEROLO
FUMARATO
Concurrent use of FORMOTEROL and QT PROLONGING DRUGS may result in increased risk of ventricular arrhythmias.
2,339
C08DA01-C10AA05 VERAPAMIL CLORIDRATO-ATORVASTATINA CALCIO TRIIDRATO
0.5%
414
0.5%
5.6
Concurrent use of ATORVASTATIN and VERAPAMIL may result in increased exposure to atorvastatin and an increased risk of myopathy or
rhabdomyolysis.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
J01FA09-J01MA12
CLARITROMICINA-LEVOFLOXACINA EMIIDRATO
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
2,330
0.5%
1.825
2.3%
1.3
0.2%
12.6
Concurrent use of CLARITHROMYCIN and LEVOFLOXACIN may result in an increased risk of QT interval prolongation.
N03AG01-N03AX09 MAGNESIO VALPROATO-LAMOTRIGINA
2,263
0.5%
180
Concurrent use of LAMOTRIGINE and VALPROIC ACID may result in increased elimination half-life of lamotrigine leading to lamotrigine
toxicity (fatigue, drowsiness, ataxia) and an increased risk of life-threatening rashes.
C03EA01-C09AA02 AMILORIDE CLORIDRATO/IDROCLOROTIAZIDE-ENALAPRIL2,219
MALEATO0.5%
463
0.6%
4.8
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
J01FA10-J01MA12
AZITROMICINA DIIDRATO-LEVOFLOXACINA EMIIDRATO 2,144
0.5%
1.673
2.1%
1.3
0.6%
4.3
Concurrent use of AZITHROMYCIN and LEVOFLOXACIN may result in an increased risk of QT interval prolongation.
2,117
0.5%
A02BC05-N06AB04 ESOMEPRAZOLO MAGNESIO TRIIDRATO-CITALOPRAM BROMIDRATO
490
Concurrent use of CITALOPRAM and ESOMEPRAZOLE may result in increased citalopram exposure and increased risk of QT interval
prolongation.
C09AA05-C09CA03 RAMIPRIL-VALSARTAN
1,954
0.4%
421
0.5%
4.6
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
B01AA03-J01MA12 WARFARIN SODICO-LEVOFLOXACINA EMIIDRATO
1,948
0.4%
1.277
1.6%
1.5
0.4%
930
1.2%
2.0
Concurrent use of LEVOFLOXACIN and WARFARIN may result in an increased risk of bleeding.
J01MA12-J02AC01
LEVOFLOXACINA EMIIDRATO-FLUCONAZOLO
1,888
Concurrent use of FLUCONAZOLE and LEVOFLOXACIN may result in an increased risk of QTc prolongation and torsades de pointes.
C09AA05-C09CA01 RAMIPRIL-LOSARTAN POTASSICO
1,870
0.4%
336
0.4%
5.6
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
C03EB01-C09AA05 FUROSEMIDE/SPIRONOLATTONE-RAMIPRIL
1,847
0.4%
367
0.5%
5.0
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
C03CA01-C07AA07 FUROSEMIDE-SOTALOLO CLORIDRATO
1,798
0.4%
427
0.5%
4.2
Concurrent use of SOTALOL and DIURETICS may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
A02BX13-C09AA05 SODIO ALGINATO/POTASSIO BICARBONATO-RAMIPRIL
1,764
0.4%
522
0.7%
3.4
1,757
0.4%
261
0.3%
6.7
Concurrent use of POTASSIUM and RAMIPRIL may result in hyperkalemia.
C02AC01-C07AB07 CLONIDINA-BISOPROLOLO EMIFUMARATO
Concurrent use of BISOPROLOL and CLONIDINE may result in increased risk of sinus bradycardia; exaggerated clonidine withdrawal
response (acute hypertension).
N02AB03-N02AB03 FENTANIL-FENTANIL
1,753
0.4%
229
0.3%
7.7
1.4%
1.5
712
0.9%
2.3
846
1.1%
2.0
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
J01FA10-R03AK06
1,718
0.4%
1.119
AZITROMICINA DIIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
Concurrent use of AZITHROMYCIN and SALMETEROL may result in an increased risk of QT interval prolongation.
B01AB05-B01AC05 ENOXAPARINA SODICA-TICLOPIDINA CLORIDRATO
1,655
0.4%
Concurrent use of TICLOPIDINE and ANTICOAGULANTS may result in an increased risk of bleeding.
C01BD01-J01MA12 AMIODARONE CLORIDRATO-LEVOFLOXACINA EMIIDRATO1,654
0.4%
Concurrent use of LEVOFLOXACIN and CLASS III ANTIARRHYTHMIC AGENTS may result in an increased risk of cardiotoxicity (QT
prolongation, torsades de pointes, cardiac arrest).
C08CA01-C10BA02 AMLODIPINA BESILATO-EZETIMIBE/SIMVASTATINA
1,550
0.3%
330
0.4%
4.7
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including
rhabdomyolysis.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
1,540
C09BA02-M04AA01 ENALAPRIL MALEATO/IDROCLOROTIAZIDE-ALLOPURINOLO
0.3%
395
0.5%
3.9
Concurrent use of ALLOPURINOL and ENALAPRIL may result in hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions,
anaphylactic coronary spasm).
N05AH04-N06AB04 QUETIAPINA FUMARATO-CITALOPRAM BROMIDRATO
1,488
0.3%
319
0.4%
4.7
329
0.4%
4.3
Concurrent use of CITALOPRAM and QUETIAPINE may result in increased risk of QT interval prolongation.
A02BC01-B01AC04 OMEPRAZOLO-CLOPIDOGREL
1,423
0.3%
Concurrent use of CLOPIDOGREL and OMEPRAZOLE may result in reduction in clinical efficacy of clopidogrel and increased risk for
thrombosis.
N02AA99-N02AB03 OXICODONE CLORIDRATO/PARACETAMOLO-FENTANIL
1,406
0.3%
264
0.3%
5.3
0.3%
5.6
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
C01AA05-C08DA01 DIGOSSINA-VERAPAMIL CLORIDRATO
1,405
0.3%
249
Concurrent use of DIGOXIN and VERAPAMIL may result in increased serum digoxin concentrations and risk of digitalis toxicity.
B01AC05-N06AB04 TICLOPIDINA CLORIDRATO-CITALOPRAM BROMIDRATO 1,394
0.3%
252
0.3%
5.5
314
0.4%
4.4
672
0.8%
2.0
Concurrent use of CITALOPRAM and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
B01AC05-N06AB05 TICLOPIDINA CLORIDRATO-PAROXETINA CLORIDRATO
1,372
0.3%
Concurrent use of PAROXETINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
B01AB05-M01AB05 ENOXAPARINA SODICA-DICLOFENAC POTASSICO
1,358
0.3%
Concurrent use of LOW MOLECULAR WEIGHT HEPARINS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in an
increased risk of bleeding.
J01FA09-J01FA10
CLARITROMICINA-AZITROMICINA DIIDRATO
1,336
0.3%
1.184
1.5%
1.1
521
0.7%
2.5
716
0.9%
1.8
Concurrent use of AZITHROMYCIN and CLARITHROMYCIN may result in an increased risk of QT interval prolongation.
B01AB05-N06AB05 ENOXAPARINA SODICA-PAROXETINA CLORIDRATO
1,292
0.3%
Concurrent use of PAROXETINE and ANTICOAGULANTS may result in an increased risk of bleeding.
1,290
A10BD02-J01MA12 CLORPROPAMIDE/METFORMINA-LEVOFLOXACINA EMIIDRATO
0.3%
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
A02BC05-B01AC04 ESOMEPRAZOLO MAGNESIO TRIIDRATO-CLOPIDOGREL
1,268
0.3%
305
0.4%
4.2
Concurrent use of CLOPIDOGREL and ESOMEPRAZOLE may result in reduction in clinical efficacy of clopidogrel and increased risk for
thrombosis.
N02AA05-N02AB03 OXICODONE CLORIDRATO-FENTANIL
1,253
0.3%
222
0.3%
5.6
0.3%
5.9
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
C02AC01-C07AB12 CLONIDINA-NEBIVOLOLO CLORIDRATO
1,251
0.3%
212
Concurrent use of CLONIDINE and NEBIVOLOL may result in increased risk of sinus bradycardia; exaggerated clonidine withdrawal
response (acute hypertension).
265
0.3%
4.7
1,213
0.3%
312
C01BD01-R03AK06 AMIODARONE CLORIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
0.4%
3.9
885
1.1%
1.4
426
0.5%
2.8
261
0.3%
4.5
B01AC05-N06AB06 TICLOPIDINA CLORIDRATO-SERTRALINA CLORIDRATO
1,249
0.3%
Concurrent use of SERTRALINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
Concurrent use of AMIODARONE and SALMETEROL may result in an increased risk of QT interval prolongation.
C10AA01-J01FA10
SIMVASTATINA-AZITROMICINA DIIDRATO
1,198
0.3%
Concurrent use of AZITHROMYCIN and SIMVASTATIN may result in an increased risk of rhabdomyolysis.
B01AB05-N06AB06 ENOXAPARINA SODICA-SERTRALINA CLORIDRATO
1,182
0.3%
Concurrent use of SERTRALINE and ANTICOAGULANTS may result in an increased risk of bleeding.
C01AA05-C03EB01 DIGOSSINA-FUROSEMIDE/SPIRONOLATTONE
1,171
0.3%
Concurrent use of DIGOXIN and SPIRONOLACTONE may result in digoxin toxicity (nausea, vomiting, cardiac arrhythmias).
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
1,152
0.3%
605
0.8%
1.9
0.3%
255
0.3%
4.5
B01AB06-B01AC06 NADROPARINA CALCICA-ACIDO ACETILSALICILICO
Concurrent use of ASPIRIN and HEPARIN may result in an increased risk of bleeding.
C09AA05-C09DA03 RAMIPRIL-VALSARTAN/IDROCLOROTIAZIDE
1,149
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
C01AA05-C03DA01 DIGOSSINA-SPIRONOLATTONE
1,148
0.3%
196
0.2%
5.9
Concurrent use of DIGOXIN and SPIRONOLACTONE may result in digoxin toxicity (nausea, vomiting, cardiac arrhythmias).
B01AC05-M01AE01 TICLOPIDINA CLORIDRATO-IBUPROFENE
1,145
0.3%
492
0.6%
2.3
Concurrent use of TICLOPIDINE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased risk of gastrointestinal
bleeding.
G04CA01-J01MA12 ALFUZOSINA CLORIDRATO-LEVOFLOXACINA EMIIDRATO 1,132
0.3%
664
0.8%
1.7
1.1%
1.3
Concurrent use of ALFUZOSIN and LEVOFLOXACIN may result in an increased risk of QT interval prolongation.
C10AA01-J01FA09
SIMVASTATINA-CLARITROMICINA
1,115
0.3%
860
Concurrent use of CLARITHROMYCIN and SIMVASTATIN may result in an increased risk of myopathy or rhabdomyolysis.
C01AA05-C01BD01 DIGOSSINA-AMIODARONE CLORIDRATO
1,094
0.2%
286
0.4%
3.8
0.3%
4.6
Concurrent use of DIGOXIN and AMIODARONE may result in digoxin toxicity (nausea, vomiting, cardiac arrhythmias).
B01AA03-C03CA04 WARFARIN SODICO-TORASEMIDE
1,074
0.2%
232
Concurrent use of TORSEMIDE and WARFARIN may result in increased warfarin plasma concentrations, decreased warfarin clearance, and
elevated INR.
A10BB12-J01MA12 GLIMEPIRIDE-LEVOFLOXACINA EMIIDRATO
1,072
0.2%
586
0.7%
1.8
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
C01BD01-C08CA05 AMIODARONE CLORIDRATO-NIFEDIPINA
1,064
0.2%
185
0.2%
5.8
Concurrent use of AMIODARONE and CALCIUM CHANNEL BLOCKERS may result in bradycardia, atrioventricular block and/or sinus
arrest.
M01AE01-N06AB05 IBUPROFENE-PAROXETINA CLORIDRATO
1,063
0.2%
599
0.8%
1.8
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
C03DA01-C09AA02 SPIRONOLATTONE-ENALAPRIL MALEATO
1,052
0.2%
156
0.2%
6.7
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
B01AA03-N06AB05 WARFARIN SODICO-PAROXETINA CLORIDRATO
1,026
0.2%
334
0.4%
3.1
245
0.3%
4.2
1.0%
1.3
Concurrent use of PAROXETINE and ANTICOAGULANTS may result in an increased risk of bleeding.
N02AB03-N02BE51 FENTANIL-PARACETAMOLO/CODEINA FOSFATO
1,025
0.2%
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
C10AA05-J01FA09
ATORVASTATINA CALCIO TRIIDRATO-CLARITROMICINA 1,024
0.2%
762
Concurrent use of ATORVASTATIN and CLARITHROMYCIN may result in increased atorvastatin exposure and an increased risk of
myopathy or rhabdomyolysis.
B01AA03-N06AB06 WARFARIN SODICO-SERTRALINA CLORIDRATO
1,004
0.2%
315
0.4%
3.2
109
0.1%
9.0
174
0.2%
5.6
Concurrent use of SERTRALINE and ANTICOAGULANTS may result in an increased risk of bleeding.
B01AC05-N06AX16 TICLOPIDINA CLORIDRATO-VENLAFAXINA CLORIDRATO
983
0.2%
Concurrent use of VENLAFAXINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
N06AX11-N06AX16 MIRTAZAPINA-VENLAFAXINA CLORIDRATO
972
0.2%
Concurrent use of MIRTAZAPINE and VENLAFAXINE may result in an increased risk of serotonin syndrome.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
968
0.2%
C03EA01-C09AA04 AMILORIDE CLORIDRATO/IDROCLOROTIAZIDE-PERINDOPRIL
ARGININA
251
% (2)
Int/Ass
0.3%
3.9
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
J01FA09-R03AK07
954
0.2%
774
1.0%
CLARITROMICINA-BECLOMETASONE DIPROPRIONATO/FORMOTEROLO
FUMARATO
DIIDRATO
1.2
Concurrent use of FORMOTEROL and QT PROLONGING DRUGS may result in increased risk of ventricular arrhythmias.
B01AB05-N06AB04 ENOXAPARINA SODICA-CITALOPRAM BROMIDRATO
938
0.2%
345
0.4%
2.7
166
0.2%
5.6
Concurrent use of CITALOPRAM and ANTICOAGULANTS may result in an increased risk of bleeding.
0.2%
C03EA01-C09AA03 AMILORIDE CLORIDRATO/IDROCLOROTIAZIDE-LISINOPRIL 925
DIIDRATO
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
0.2%
249
0.3%
3.6
899
0.2%
N02AA05-N02AA99 OXICODONE CLORIDRATO-OXICODONE CLORIDRATO/PARACETAMOLO
176
0.2%
5.1
432
0.5%
2.0
467
0.6%
1.8
B01AA07-B01AC06 ACENOCUMAROLO-ACIDO ACETILSALICILICO
905
Concurrent use of DICUMAROL and ASPIRIN may result in an increased risk of bleeding.
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
J01MA12-N05AH04 LEVOFLOXACINA EMIIDRATO-QUETIAPINA FUMARATO
884
0.2%
Concurrent use of LEVOFLOXACIN and QUETIAPINE may result in an increased risk of QT prolongation.
B01AB05-M01AE03 ENOXAPARINA SODICA-KETOPROFENE
863
0.2%
Concurrent use of LOW MOLECULAR WEIGHT HEPARINS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in an
increased risk of bleeding.
N06AB04-N06AX05 CITALOPRAM BROMIDRATO-TRAZODONE CLORIDRATO
858
0.2%
207
0.3%
4.1
Concurrent use of CITALOPRAM and TRAZODONE may result in an increased risk of QT interval prolongation and serotonin syndrome
(hypertension, hyperthermia, myoclonus, mental status changes).
850
0.2%
C07AG02-R03AK06 CARVEDILOLO-SALMETEROLO XINAFOATO/FLUTICASONE PROPIONATO
211
0.3%
4.0
Concurrent use of BETA-ADRENERGIC BLOCKERS and BETA-2 AGONISTS may result in decreased effectiveness of either the
beta-adrenergic blocker and/or the beta-2 agonist.
847
B01AC06-M01AB15 ACIDO ACETILSALICILICO-KETOROLAC SALE DI TROMETAMOLO
0.2%
538
0.7%
1.6
Concurrent use of ASPIRIN and KETOROLAC may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal
bleeding, and/or perforation) and possible increase in serum ketorolac levels.
J01MA12-N06AB04 LEVOFLOXACINA EMIIDRATO-CITALOPRAM BROMIDRATO 843
0.2%
520
0.7%
1.6
310
0.4%
2.7
Concurrent use of CITALOPRAM and LEVOFLOXACIN may result in increased risk of QT interval prolongation.
N02AX02-N06AA09 TRAMADOLO CLORIDRATO-AMITRIPTILINA CLORIDRATO
833
0.2%
Concurrent use of AMITRIPTYLINE and TRAMADOL may result in an increased risk of seizures; increased concentrations of tramadol and
decreased concentrations of tramadol active metabolite, M1.
829
0.2%
287FUMARATO
0.4% DIIDRATO
2.9
C07AB07-R03AK07 BISOPROLOLO EMIFUMARATO-BECLOMETASONE DIPROPRIONATO/FORMOTEROLO
Concurrent use of BETA-ADRENERGIC BLOCKERS and BETA-2 AGONISTS may result in decreased effectiveness of either the
beta-adrenergic blocker and/or the beta-2 agonist.
N02AX02-N06AB04 TRAMADOLO CLORIDRATO-CITALOPRAM BROMIDRATO
825
0.2%
212
0.3%
3.9
Concurrent use of CITALOPRAM and TRAMADOL may result in an increased risk of seizures and serotonin syndrome (hypertension,
hyperthermia, myoclonus, mental status changes).
C02AC01-C07AB03 CLONIDINA-ATENOLOLO
824
0.2%
179
0.2%
4.6
Concurrent use of ATENOLOL and CLONIDINE may result in increased risk of sinus bradycardia; exaggerated clonidine withdrawal
response (acute hypertension).
255
0.3%
3.2
817
0.2%
308
C07AB12-R03AK06 NEBIVOLOLO CLORIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
0.4%
2.7
B01AA03-N06AB04 WARFARIN SODICO-CITALOPRAM BROMIDRATO
821
0.2%
Concurrent use of CITALOPRAM and ANTICOAGULANTS may result in an increased risk of bleeding.
Concurrent use of BETA-ADRENERGIC BLOCKERS and BETA-2 AGONISTS may result in decreased effectiveness of either the
beta-adrenergic blocker and/or the beta-2 agonist.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
814
0.2%
203
0.3%
4.0
J02AC01-N02AB03 FLUCONAZOLO-FENTANIL
Concurrent use of FENTANYL and FLUCONAZOLE may result in increased or prolonged opioid effects (CNS depression, respiratory
depression).
C10AA07-J01FA09
ROSUVASTATINA SALE DI CALCIO-CLARITROMICINA
810
0.2%
588
0.7%
1.4
299
0.4%
2.7
Concurrent use of CLARITHROMYCIN and ROSUVASTATIN may result in increased risk of rhabdomyolysis.
J01EE01-J02AC01
TRIMETOPRIM/SULFAMETOXAZOLO-FLUCONAZOLO
809
0.2%
Concurrent use of COTRIMOXAZOLE and FLUCONAZOLE may result in an increased risk of cardiotoxicity (QT prolongation, torsades de
pointes, cardiac arrest).
N02AX02-N06AX16 TRAMADOLO CLORIDRATO-VENLAFAXINA CLORIDRATO
805
0.2%
127
0.2%
6.3
187
0.2%
4.3
401
0.5%
2.0
Concurrent use of TRAMADOL and VENLAFAXINE may result in an increased risk of serotonin syndrome.
B01AC05-N06AB10 TICLOPIDINA CLORIDRATO-ESCITALOPRAM OSSALATO
804
0.2%
Concurrent use of ESCITALOPRAM and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
M01AE01-N06AB06 IBUPROFENE-SERTRALINA CLORIDRATO
799
0.2%
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
B01AA03-J01CA04
WARFARIN SODICO-AMOXICILLINA TRIIDRATO
793
0.2%
570
0.7%
1.4
0.2%
282
0.4%
2.8
Concurrent use of AMOXICILLIN and WARFARIN may result in an increased risk of bleeding.
N02AX02-N06AB05 TRAMADOLO CLORIDRATO-PAROXETINA CLORIDRATO
776
Concurrent use of PAROXETINE and TRAMADOL may result in an increased risk of seizures and serotonin syndrome (hypertension,
hyperthermia, myoclonus, mental status changes); a decrease in the analgesic effect of tramadol.
G04CA02-J01FA09
TAMSULOSINA CLORIDRATO-CLARITROMICINA
765
0.2%
476
0.6%
1.6
0.4%
2.2
Concurrent use of TAMSULOSIN and STRONG CYP3A4 INHIBITORS may result in increased tamsulosin exposure.
B01AC05-M01AB05 TICLOPIDINA CLORIDRATO-DICLOFENAC POTASSICO
758
0.2%
343
Concurrent use of TICLOPIDINE and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in increased risk of gastrointestinal
bleeding.
C07AA07-C09DA03 SOTALOLO CLORIDRATO-VALSARTAN/IDROCLOROTIAZIDE 739
0.2%
165
0.2%
4.5
Concurrent use of SOTALOL and DIURETICS may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
M01AE01-N06AB04 IBUPROFENE-CITALOPRAM BROMIDRATO
731
0.2%
369
0.5%
2.0
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
J01MA12-R03DA04 LEVOFLOXACINA EMIIDRATO-TEOFILLINA
728
0.2%
335
0.4%
2.2
Concurrent use of THEOPHYLLINE and LEVOFLOXACIN may result in theophylline toxicity (nausea, vomiting, palpitations, seizures).
C07AA07-C09BA05 SOTALOLO CLORIDRATO-RAMIPRIL/IDROCLOROTIAZIDE
722
0.2%
112
0.1%
6.4
Concurrent use of SOTALOL and DIURETICS may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
J01MA12-N06AX05 LEVOFLOXACINA EMIIDRATO-TRAZODONE CLORIDRATO
722
0.2%
376
0.5%
1.9
54
0.1%
13.4
117
0.1%
6.1
569
0.7%
1.2
Concurrent use of LEVOFLOXACIN and TRAZODONE may result in an increased risk of QT interval prolongation.
N03AA02-N03AE01 FENOBARBITAL-CLONAZEPAM
721
0.2%
Concurrent use of BARBITURATES and BENZODIAZEPINES may result in additive respiratory depression.
B01AC05-N06AX21 TICLOPIDINA CLORIDRATO-DULOXETINA CLORIDRATO
710
0.2%
Concurrent use of DULOXETINE and ANTIPLATELET AGENTS may result in an increased risk of bleeding.
J01FA09-R03BA05
CLARITROMICINA-FLUTICASONE PROPIONATO
710
0.2%
Concurrent use of CLARITHROMYCIN and FLUTICASONE may result in increased fluticasone plasma concentration and reduced plasma
cortisol concentration.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
706
0.2%
169
0.2%
4.2
C01AA05-C09DA03 DIGOSSINA-VALSARTAN/IDROCLOROTIAZIDE
Concurrent use of DIGITALIS GLYCOSIDES and THIAZIDE DIURETICS may result in digitalis toxicity (nausea, vomiting, arrhythmias).
C01BD01-C08CA13 AMIODARONE CLORIDRATO-LERCANIDIPINA CLORIDRATO 703
0.2%
157
0.2%
4.5
Concurrent use of AMIODARONE and CALCIUM CHANNEL BLOCKERS may result in bradycardia, atrioventricular block and/or sinus
arrest.
C01BD01-C07AB02 AMIODARONE CLORIDRATO-METOPROLOLO TARTRATO
702
0.2%
210
0.3%
3.3
Concurrent use of AMIODARONE and BETA-ADRENERGIC BLOCKERS may result in hypotension, bradycardia, or cardiac arrest.
N02AX02-N06AX21 TRAMADOLO CLORIDRATO-DULOXETINA CLORIDRATO
697
0.2%
146
0.2%
4.8
209
0.3%
3.3
0.2%
3.8
197
0.2%
3.4
490
0.6%
1.4
0.2%
3.7
Concurrent use of DULOXETINE and TRAMADOL may result in an increased risk of serotonin syndrome.
683
N02AA05-N02AA59 OXICODONE CLORIDRATO-PARACETAMOLO/CODEINA FOSFATO
0.2%
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
C10AA07-C10AB05 ROSUVASTATINA SALE DI CALCIO-FENOFIBRATO
682
0.2%
181
Concurrent use of FENOFIBRATE and ROSUVASTATIN may result in an increased risk of myopathy or rhabdomyolysis.
675
0.2%
A02BX13-C09AA02 SODIO ALGINATO/POTASSIO BICARBONATO-ENALAPRIL MALEATO
Concurrent use of ENALAPRIL and POTASSIUM may result in hyperkalemia.
J01FA10-J02AC01
AZITROMICINA DIIDRATO-FLUCONAZOLO
673
0.2%
Concurrent use of AZITHROMYCIN and FLUCONAZOLE may result in an increased risk of QT interval prolongation.
C09AA05-C09CA07 RAMIPRIL-TELMISARTAN
670
0.2%
183
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
C01BC04-C09DA04 FLECAINIDE ACETATO-IRBESARTAN/IDROCLOROTIAZIDE
663
0.1%
90
0.1%
7.4
Concurrent use of FLECAINIDE and HYDROCHLOROTHIAZIDE may result in increased risk of electrolyte imbalance and subsequent
cardiotoxicity.
B01AB06-C01DA02 NADROPARINA CALCICA-NITROGLICERINA
660
0.1%
158
0.2%
4.2
277
0.3%
2.4
0.2%
3.5
Concurrent use of HEPARIN and NITROGLYCERIN may result in a decrease in partial thromboplastin time.
C01BC03-J01MA12 PROPAFENONE CLORIDRATO-LEVOFLOXACINA EMIIDRATO 659
0.1%
Concurrent use of LEVOFLOXACIN and PROPAFENONE may result in increased risk of QT interval prolongation.
C01AA05-C03EA01 DIGOSSINA-AMILORIDE CLORIDRATO/IDROCLOROTIAZIDE 658
0.1%
188
Concurrent use of DIGITALIS GLYCOSIDES and THIAZIDE DIURETICS may result in digitalis toxicity (nausea, vomiting, arrhythmias).
M01AB05-N06AB05 DICLOFENAC POTASSICO-PAROXETINA CLORIDRATO
657
0.1%
374
0.5%
1.8
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
C09AA05-C09CA08 RAMIPRIL-OLMESARTAN MEDOXOMIL
656
0.1%
222
0.3%
3.0
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
653
0.1%
176
G04CA01-R03AK06 ALFUZOSINA CLORIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
0.2%
3.7
272
0.3%
2.4
287
0.4%
2.3
Concurrent use of ALFUZOSIN and SALMETEROL may result in an increased risk of QT interval prolongation.
B01AB05-N06AB10 ENOXAPARINA SODICA-ESCITALOPRAM OSSALATO
648
0.1%
Concurrent use of ESCITALOPRAM and ANTICOAGULANTS may result in an increased risk of bleeding.
647
B01AB05-M01AB15 ENOXAPARINA SODICA-KETOROLAC SALE DI TROMETAMOLO
0.1%
Concurrent use of LOW MOLECULAR WEIGHT HEPARINS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in an
increased risk of bleeding.
N02AB03-N06AB05 FENTANIL-PAROXETINA CLORIDRATO
645
0.1%
118
0.1%
5.5
Concurrent use of FENTANYL and PAROXETINE may result in increased risk of serotonin syndrome or neuroleptic malignant syndrome-like
reactions.
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
642
0.1%
174
0.2%
3.7
A03FA01-N05AD01 METOCLOPRAMIDE CLORIDRATO-ALOPERIDOLO
Concurrent use of METOCLOPRAMIDE and ANTIPSYCHOTICS may result in an increased risk of extrapyramidal reactions or neuroleptic
malignant syndrome.
0.1%
361
0.5%
1.7
0.1%
A10AB04-J01MA12 INSULINA LISPRO DA DNA RICOMBINANTE-LEVOFLOXACINA629
EMIIDRATO
372
0.5%
1.7
B01AB05-B01AB06 ENOXAPARINA SODICA-NADROPARINA CALCICA
630
Concurrent use of ENOXAPARIN and HEPARIN may result in increased risk of bleeding.
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
N02AA01-N02AA05 MORFINA CLORIDRATO-OXICODONE CLORIDRATO
629
0.1%
199
0.3%
3.2
0.1%
5.7
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
N02AB03-N06AB06 FENTANIL-SERTRALINA CLORIDRATO
626
0.1%
110
Concurrent use of FENTANYL and SERTRALINE may result in increased risk of serotonin syndrome or neuroleptic malignant syndrome-like
reactions.
C03EB01-C09AA02 FUROSEMIDE/SPIRONOLATTONE-ENALAPRIL MALEATO
621
0.1%
133
0.2%
4.7
Concurrent use of POTASSIUM-SPARING DIURETICS and ANGIOTENSIN CONVERTING ENZYME INHIBITORS may result in
hyperkalemia.
N02AB03-N06AX05 FENTANIL-TRAZODONE CLORIDRATO
610
0.1%
106
0.1%
5.8
Concurrent use of FENTANYL and TRAZODONE may result in increased risk of serotonin syndrome (hypertension, hyperthermia,
myoclonus, mental status changes).
N02AB03-N06AB04 FENTANIL-CITALOPRAM BROMIDRATO
606
0.1%
103
0.1%
5.9
199
0.3%
3.0
Concurrent use of CITALOPRAM and FENTANYL may result in increased risk of serotonin syndrome.
N02AX02-N06AB06 TRAMADOLO CLORIDRATO-SERTRALINA CLORIDRATO
606
0.1%
Concurrent use of SERTRALINE and TRAMADOL may result in an increased risk of seizures and serotonin syndrome (hypertension,
hyperthermia, myoclonus, mental status changes).
B01AB05-B01AC04 ENOXAPARINA SODICA-CLOPIDOGREL
604
0.1%
280
0.4%
2.2
84
0.1%
7.2
Concurrent use of CLOPIDOGREL and ANTICOAGULANTS may result in an increased risk of bleeding.
C01BC04-C09DA03 FLECAINIDE ACETATO-VALSARTAN/IDROCLOROTIAZIDE
603
0.1%
Concurrent use of FLECAINIDE and HYDROCHLOROTHIAZIDE may result in increased risk of electrolyte imbalance and subsequent
cardiotoxicity.
N02AX02-N06AB10 TRAMADOLO CLORIDRATO-ESCITALOPRAM OSSALATO
590
0.1%
173
0.2%
3.4
Concurrent use of TRAMADOL and ESCITALOPRAM may result in an increased risk of seizures and serotonin syndrome (hypertension,
hyperthermia, myoclonus, mental status changes).
B01AA03-N06AB10 WARFARIN SODICO-ESCITALOPRAM OSSALATO
581
0.1%
203
0.3%
2.9
405
0.5%
1.4
Concurrent use of ESCITALOPRAM and ANTICOAGULANTS may result in an increased risk of bleeding.
A10AE04-J01MA12 INSULINA GLARGINE-LEVOFLOXACINA EMIIDRATO
577
0.1%
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
N03AA03-N03AF01 PRIMIDONE-CARBAMAZEPINA
577
0.1%
32
0.0%
18.0
0.4%
1.8
Concurrent use of PRIMIDONE and CYP3A4 SUBSTRATES may result in decreased exposure of CYP3A4 substrates.
M01AE01-N06AB10 IBUPROFENE-ESCITALOPRAM OSSALATO
576
0.1%
326
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
N02AX02-N06AX05 TRAMADOLO CLORIDRATO-TRAZODONE CLORIDRATO
565
0.1%
153
0.2%
3.7
Concurrent use of TRAMADOL and TRAZODONE may result in increased risk of serotonin syndrome (hypertension, hyperthermia,
myoclonus, mental status changes).
B01AA03-B01AC05 WARFARIN SODICO-TICLOPIDINA CLORIDRATO
563
0.1%
Concurrent use of TICLOPIDINE and ANTICOAGULANTS may result in an increased risk of bleeding.
175
0.2%
3.2
Bergamo 2011/2012 - IF per coppia ATC con descrizione
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
ATC
Descrizione-Descrizione
Interazioni
% (1)
Assistiti
% (2)
Int/Ass
563
0.1%
67
0.1%
8.4
286
0.4%
2.0
C02AC01-C08DA01 CLONIDINA-VERAPAMIL CLORIDRATO
Concurrent use of CLONIDINE and VERAPAMIL may result in increased incidence of sinus bradycardia.
B01AC06-M01AE02 ACIDO ACETILSALICILICO-NAPROXENE
561
0.1%
Concurrent use of ASPIRIN and NAPROXEN may result in increased risk of serious gastrointestinal adverse effects (ulceration, bleeding,
perforation).
C01BD01-C07AB12 AMIODARONE CLORIDRATO-NEBIVOLOLO CLORIDRATO
550
0.1%
151
0.2%
3.6
Concurrent use of AMIODARONE and BETA-ADRENERGIC BLOCKERS may result in hypotension, bradycardia, or cardiac arrest.
C07AB07-C08DA01 BISOPROLOLO EMIFUMARATO-VERAPAMIL CLORIDRATO
548
0.1%
149
0.2%
3.7
93
0.1%
5.9
Concurrent use of VERAPAMIL and BETA-ADRENERGIC BLOCKERS may result in hypotension, bradycardia.
C09BA05-C09CA03 RAMIPRIL/IDROCLOROTIAZIDE-VALSARTAN
548
0.1%
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
C07AA07-C09DA04 SOTALOLO CLORIDRATO-IRBESARTAN/IDROCLOROTIAZIDE547
0.1%
119
0.1%
4.6
Concurrent use of SOTALOL and DIURETICS may result in an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac
arrest).
C09AA05-C09DA07 RAMIPRIL-TELMISARTAN/IDROCLOROTIAZIDE
547
0.1%
129
0.2%
4.2
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in
increased risk of adverse events (ie, hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
M01AB15-M01AE01 KETOROLAC SALE DI TROMETAMOLO-IBUPROFENE
542
0.1%
314
0.4%
1.7
Concurrent use of KETOROLAC and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in enhanced gastrointestinal adverse
effects (peptic ulcers, gastrointestinal bleeding and/or perforation).
N02AA59-N02AE01 PARACETAMOLO/CODEINA FOSFATO-BUPRENORFINA
536
0.1%
137
0.2%
3.9
Concurrent use of OPIOID ANALGESICS and OPIOID AGONISTS/ANTAGONISTS may result in precipitation of withdrawal symptoms
(abdominal cramps, nausea, vomiting, lacrimation, rhinorrhea, anxiety, restlessness, elevation of temperature or piloerection).
N02AB03-N06AA09 FENTANIL-AMITRIPTILINA CLORIDRATO
534
0.1%
139
0.2%
3.8
Concurrent use of AMITRIPTYLINE and FENTANYL may result in an increased risk of serotonin syndrome (hypertension, hyperthermia,
myoclonus, mental status changes).
B01AA03-C10BA02 WARFARIN SODICO-EZETIMIBE/SIMVASTATINA
529
0.1%
157
0.2%
3.4
Concurrent use of SIMVASTATIN and WARFARIN may result in increased risk of bleeding and an increased risk of rhabdomyolysis.
C01AA05-C09BA05 DIGOSSINA-RAMIPRIL/IDROCLOROTIAZIDE
529
0.1%
99
0.1%
5.3
Concurrent use of DIGITALIS GLYCOSIDES and THIAZIDE DIURETICS may result in digitalis toxicity (nausea, vomiting, arrhythmias).
108
0.1%
4.9
525
0.1%
173
N06AB04-R03AK06 CITALOPRAM BROMIDRATO-SALMETEROLO XINAFOATO/FLUTICASONE
PROPIONATO
0.2%
3.0
0.3%
2.5
0.4%
1.7
B01AA03-N06AX16 WARFARIN SODICO-VENLAFAXINA CLORIDRATO
526
0.1%
Concurrent use of VENLAFAXINE and ANTICOAGULANTS may result in an increased risk of bleeding.
Concurrent use of CITALOPRAM and SALMETEROL may result in an increased risk of QT interval prolongation.
518
N02AA01-N02AA59 MORFINA CLORIDRATO-PARACETAMOLO/CODEINA FOSFATO
0.1%
205
Concurrent use of OPIOID ANALGESICS and OPIOID ANALGESICS may result in additive respiratory depression.
A10AB05-J01MA12 INSULINA ASPART-LEVOFLOXACINA EMIIDRATO
517
0.1%
303
Concurrent use of FLUOROQUINOLONES and ANTIDIABETIC AGENTS may result in changes in blood glucose and increased risk of
hypoglycemia or hyperglycemia.
514
M01AB05-M01AB15 DICLOFENAC POTASSICO-KETOROLAC SALE DI TROMETAMOLO
0.1%
334
0.4%
1.5
Concurrent use of KETOROLAC and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in enhanced gastrointestinal adverse
effects (peptic ulcers, gastrointestinal bleeding and/or perforation).
M01AB05-N06AB06 DICLOFENAC POTASSICO-SERTRALINA CLORIDRATO
513
0.1%
257
0.3%
2.0
Concurrent use of SELECTIVE SEROTONIN REUPTAKE INHIBITORS and NONSTEROIDAL ANTIINFLAMMATORY AGENTS may result in
an increased risk of bleeding.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Non specificato
Discreta
8.141
2.670
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an increased risk of bleeding.
Maggiore
CARDIOASPIRIN
COUMADIN
Ritardato
Eccellente
5.429
1.797
La contemporanea assunzione di ASPIRINA e WARFARINA può portare ad un aumento del rischio di sanguinamento
Maggiore
CLEXANE
COUMADIN
Non specificato
Discreta
3.482
1.803
L'utilizzo concomitante di enoxaparina e warfarin può portare ad un aumentato rischio di sanguinamento
CORDARONE
COUMADIN
CARDIOASPIRIN
PLAVIX
Maggiore
Numero: Assistiti:
Ritardato
Eccellente
3.021
936
La contemporanea assunzione di AMIODARONE e WARFARIN può portare ad un aumento del rischio di sanguinamento.
Maggiore
CLEXANE T
COUMADIN
Non specificato
Discreta
2.827
1.287
L'utilizzo concomitante di enoxaparina e warfarin può portare ad un aumentato rischio di sanguinamento
NORVASC
SIVASTIN
Nelle 24 ore
Buona
2.619
539
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Discreta
SEROQUEL
TRITTICO
2.478
491
Concurrent use of QUETIAPINE and TRAZODONE may result in an increased risk of QT interval prolongation.
BRUFEN
CLEXANE
Maggiore
Maggiore
Non specificato
Buona
2.125
1.173
L'utilizzo concomitante di EPARINE A BASSO PESO MOLECOLARE e di FANS può aumentare il rischio di emorragia.
Maggiore
CARDIOASPIRIN
ZOLOFT
Non specificato
Buona
1.981
584
L'utilizzo concomitante di sertralina e farmaci antiaggreganti può portare ad un aumentato rischio di sanguinamento
Maggiore
CARDIOASPIRIN
CIPRALEX
Non specificato
Buona
1.888
570
L'utilizzo concomitante di ESCITALOPRAM e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di sanguinamento.
Maggiore
AMLODIPINA DOC G.
SIMVASTATINA DOC
Nelle 24 ore
Buona
1.744
465
1.729
140
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Ritardato
Eccellente
DEPAKIN
LAMICTAL
La contemporanea assunzione di LAMOTRIGINA e ACIDO VALPROICO può causare un aumento dell’emivita di eliminazione della lamotrigina portando a tossicità da lamotrigina
(affaticamento, sonnolenza, atassia) e un aumento del rischio di rash potenzialmente mortali.
Maggiore
Ritardato
Eccellente
1.723
AMIODARONE SANDOZ
COUMADIN
609
La contemporanea assunzione di AMIODARONE e WARFARIN può portare ad un aumento del rischio di sanguinamento.
Maggiore
CARDIOASPIRIN
CYMBALTA
Non specificato
La contemporanea assunzione di DULOXETINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Maggiore
Nelle 24 ore
AMLODIPINA M.G.
SIMVASTATINA M.G.
Buona
1.698
377
Buona
1.592
437
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Pag. 1 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Non specificato
Buona
1.565
437
L'utilizzo concomitante di ESCITALOPRAM e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di sanguinamento.
Maggiore
CARDIOASPIRIN
EFEXOR
Non specificato
Buona
1.528
258
Buona
1.469
282
CARDIOASPIRIN
ENTACT
La contemporanea assunzione di VENLAFAXINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Maggiore
Nelle 24 ore
CORDARONE
NORVASC
Numero: Assistiti:
La contemporanea assunzione di AMIODARONE e BLOCCANTI DEI CANALI DEL CALCIO può portare a bradicardia, blocco atrioventricolare e/o arresto del nodo senoatriale.
Maggiore
Ritardato
Buona
1.337
MODURETIC
TRIATEC
320
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
AMIODAR
COUMADIN
Ritardato
Eccellente
1.285
401
La contemporanea assunzione di AMIODARONE e WARFARIN può portare ad un aumento del rischio di sanguinamento.
Maggiore
DEPALGOS
OXYCONTIN
Nelle 24 ore
Buona
1.270
228
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
CARDIOASPIRIN
CITALOPRAM M.G.
Non specificato
Buona
1.268
426
Ritardato
Eccellente
1.202
394
La contemporanea assunzione di SIMVASTATINA e WARFARIN può portare ad un maggior rischio di sanguinamento e ad un aumentato rischio di rabdomiolisi.
Maggiore
Nelle 24 ore
Eccellente
AMIODARONE SANDOZ
BISOPROLOLO SAN
1.195
344
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Non specificato
CARDIOASPIRIN
SEREUPIN
Buona
1.194
339
L'utilizzo concomitante di PAROXETINA e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
COEFFERALGAN
DUROGESIC
Nelle 24 ore
Buona
1.185
258
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
CARDIOASPIRIN
XERISTAR
Non specificato
Buona
1.183
268
Buona
1.181
235
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Buona
CARDIOASPIRIN
CITALOPRAM DOC
1.162
375
L'utilizzo concomitante di CITALOPRAM e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
NORVASC
PLAVIX
Eccellente
1.160
356
Discreta
1.125
730
Maggiore
L'utilizzo concomitante di CITALOPRAM e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
COUMADIN
SIVASTIN
Maggiore
La contemporanea assunzione di DULOXETINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Maggiore
Nelle 24 ore
NORVASC
SINVACOR
Non specificato
Concurrent use of AMLODIPINE and CLOPIDOGREL may result in decreased antiplatelet effect and increased risk of thrombotic events.
Maggiore
Non specificato
ALIFLUS
LEVOXACIN
Concurrent use of LEVOFLOXACIN and SALMETEROL may result in an increased risk of QT interval prolongation.
Pag. 2 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
LANOXIN
LASITONE
Severità:
Insorgenza:
Doc.:
Maggiore
Ritardato
Buona
1.111
244
Discreta
1.093
709
La contemporanea assunzione di DIGOSSINA e SPIRONOLATTONE può portare a tossicità da digossina (nausea, vomito, aritmie)
Maggiore
Non specificato
CARDIOASPIRIN
OKI
Numero: Assistiti:
La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione
della mucosa).
Maggiore
Non specificato Buona
1.044
CARDIOASPIRIN
PAROXETINA M.G
360
L'utilizzo concomitante di PAROXETINA e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
ALDACTONE
LANOXIN
Ritardato
Buona
1.039
176
Eccellente
1.006
354
La contemporanea assunzione di SIMVASTATINA e WARFARIN può portare ad un maggior rischio di sanguinamento e ad un aumentato rischio di rabdomiolisi.
Maggiore
Non specificato Buona
CARDIOASPIRIN
SERTRALINA DOC
980
334
L'utilizzo concomitante di sertralina e farmaci antiaggreganti può portare ad un aumentato rischio di sanguinamento
Maggiore
NORVASC
SIMVASTATINA DOC
952
308
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Discreta
CARDIOASPIRIN
CLOPIDOGREL DOC G
947
353
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an increased risk of bleeding.
Maggiore
CARDIOASPIRIN
DAPAROX
Non specificato
Buona
936
311
L'utilizzo concomitante di PAROXETINA e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
ALDACTONE
TRIATEC
Ritardato
Buona
921
162
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
DUROGESIC
ORAMORPH
Nelle 24 ore
Buona
900
208
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
DUROGESIC
TACHIDOL
Maggiore
Nelle 24 ore
Buona
868
203
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
DUROGESIC
EFFENTORA
Maggiore
Nelle 24 ore
Buona
844
82
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
GAVISCON ADVANCE
TRIATEC
Maggiore
Ritardato
Buona
830
244
La contemporanea assunzione di POTASSIO e RAMIPRIL può determinare iperkaliemia.
ISOPTIN
TORVAST
Maggiore
Non specificato
Discreta
829
156
La contemporanea assunzione di DIGOSSINA e SPIRONOLATTONE può portare a tossicità da digossina (nausea, vomito, aritmie)
Maggiore
Ritardato
COUMADIN
SIMVASTATINA DOC
Nelle 24 ore
Buona
Concurrent use of ATORVASTATIN and VERAPAMIL may result in increased exposure to atorvastatin and an increased risk of myopathy or rhabdomyolysis.
Pag. 3 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Ritardato
Buona
828
188
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
CARDIOASPIRIN
SINTROM
Ritardato
Buona
816
223
L'utilizzo concomitante di dicumarolo e aspirina può portare ad un aumentato rischio di sanguinamento
CORDARONE
SEQUACOR
Nelle 24 ore
Eccellente
816
172
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Ritardato
ISOPTIN
LANOXIN
Eccellente
809
147
Concurrent use of DIGOXIN and VERAPAMIL may result in increased serum digoxin concentrations and risk of digitalis toxicity.
Maggiore
COUMADIN
SIMVASTATINA M.G.
Eccellente
807
308
La contemporanea assunzione di SIMVASTATINA e WARFARIN può portare ad un maggior rischio di sanguinamento e ad un aumentato rischio di rabdomiolisi.
Maggiore
Nelle 24 ore
Buona
DEPALGOS
DUROGESIC
803
172
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
CARDIOASPIRIN
SERTRALINA M.G.
ENAPREN
MODURETIC
Maggiore
Maggiore
L'utilizzo concomitante di sertralina e farmaci antiaggreganti può portare ad un aumentato rischio di sanguinamento
Maggiore
ENAPREN
ZYLORIC
Ritardato
Numero: Assistiti:
Non specificato
Buona
787
301
Nelle 24 ore
Discreta
783
221
La contemporanea assunzione di ALLOPURINOLO e ENALAPRIL può portare a reazioni di ipersensibilità (sindrome di Stevens-Johnson, eruzioni cutanee, spasmo coronarico
anafilattico).
Maggiore
Nelle 24 ore
Eccellente
780
CORDARONE
DILATREND
132
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Nelle 24 ore
NORVASC
SIMVASTATINA M.G.
777
240
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Buona
CARDIOASPIRIN
TICLOPIDINA DOC
725
222
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
CARDICOR
CORDARONE
Eccellente
722
142
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Non specificato
GARDENALE
RIVOTRIL
Buona
711
52
La contemporanea assunzione di BARBITURICI e BENZODIAZEPINE può portare a marcata depressione respiratoria
Maggiore
CITALOPRAM M.G.
LANSOPRAZOLO M.G.
Non specificato
Discreta
708
173
Concurrent use of CITALOPRAM and LANSOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
Maggiore
Non specificato
ALIFLUS
BISOPROLOLO SAN
Discreta
702
226
Maggiore
Nelle 24 ore
Buona
La contemporanea assunzione di BLOCCANTI BETA-ADRENERGICI e BETA-2 AGONISTI può portare ad una diminuzione di efficacia del beta-bloccante e/o del beta-2 agonista.
Pag. 4 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
CONTRAMAL
LAROXYL
Severità:
Insorgenza:
Doc.:
Maggiore
Nelle 24 ore
Discreta
Numero: Assistiti:
698
266
La contemporanea assunzione di AMITRIPTILINA e TRAMADOLO può portare ad un aumento del rischio di attacchi convulsivi per aumento delle concentrazioni di tramadolo e
diminuzione delle concentrazioni del suo metabolita attivo M1.
Maggiore
Non specificato Discreta
667
ALIFLUS
TAVANIC
422
Concurrent use of LEVOFLOXACIN and SALMETEROL may result in an increased risk of QT interval prolongation.
Maggiore
BISOPROLOLO SAN
CORDARONE
Eccellente
653
201
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Ritardato
CARDIRENE
COUMADIN
Nelle 24 ore
Eccellente
652
208
La contemporanea assunzione di ASPIRINA e WARFARINA può portare ad un aumento del rischio di sanguinamento
Maggiore
CARDIOASPIRIN
TICLOPIDINA DOROM
Non specificato
Buona
649
209
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
LASITONE
TRIATEC
Maggiore
Ritardato
Buona
649
139
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
COUMADIN
LEVOXACIN
Ritardato
Eccellente
640
461
Concurrent use of LEVOFLOXACIN and WARFARIN may result in an increased risk of bleeding.
CARDIOASPIRIN
PAROXETINA DOC GEN.
Maggiore
Non specificato
Buona
633
220
L'utilizzo concomitante di PAROXETINA e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
CARDIOASPIRIN
CLOPIDOGREL MG
Non specificato
Discreta
625
222
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an increased risk of bleeding.
Maggiore
COEFFERALGAN
DEPALGOS
Nelle 24 ore
Buona
625
291
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
CARDIOASPIRIN
TIKLID
Maggiore
Non specificato
Buona
623
162
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
LORTAAN
TRIATEC
Maggiore
Non specificato
Eccellente
616
90
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in increased risk of adverse events (ie,
hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
Maggiore
Non specificato Buona
610
CARDIOASPIRIN
VENLAFAXINA DOC
144
La contemporanea assunzione di VENLAFAXINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Maggiore
Nelle 24 ore
CARDIOASPIRIN
SELEPARINA
Eccellente
604
366
La contemporanea assunzione di ASPIRINA e EPARINA può portare ad un aumento del rischio di sanguinamento
TAREG
TRIATEC
Eccellente
604
107
Maggiore
Non specificato
Concurrent use of ANGIOTENSIN CONVERTING ENZYME INHIBITORS and ANGIOTENSIN II RECEPTOR BLOCKERS may result in increased risk of adverse events (ie,
hypotension, syncope, hyperkalemia, changes in renal function, acute renal failure).
Pag. 5 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
COEFFERALGAN
OXYCONTIN
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
CARDIRENE
PLAVIX
Severità:
Insorgenza:
Doc.:
Numero: Assistiti:
Maggiore
Nelle 24 ore
Buona
598
167
Maggiore
Non specificato
Discreta
594
226
Concurrent use of ASPIRIN and CLOPIDOGREL HYDROGEN SULFATE may result in an increased risk of bleeding.
Maggiore
MYSOLINE
TEGRETOL
Non specificato
Discreta
577
32
Concurrent use of PRIMIDONE and CYP3A4 SUBSTRATES may result in decreased exposure of CYP3A4 substrates.
Maggiore
CARDIOASPIRIN
ZARELIS
Non specificato
Buona
570
102
Discreta
561
366
La contemporanea assunzione di VENLAFAXINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Controindicato Non specificato
CARDIOASPIRIN
TORADOL
L'utilizzo concomitante di ASPIRINA e di KETOROLAC aumenta gli effetti avversi gastrointestinali (ulcera peptica, sanguinamento gastrointestinale, e/o perforazione) e i livelli sierici
di ketorolac.
Maggiore
Non specificato Discreta
561
CITALOPRAM DOC
LANSOPRAZOLO DOC G
148
Concurrent use of CITALOPRAM and LANSOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
Maggiore
Ritardato
Eccellente
554
LANOXIN
MODURETIC
167
La contemporanea assunzione di GLICOSIDI DIGITALICI e DIURETICI TIAZIDICI può portare a tossicità da digitalici (nausea, vomito, aritmie).
Maggiore
Ritardato
COUMADIN
SINVACOR
Eccellente
551
171
La contemporanea assunzione di SIMVASTATINA e WARFARIN può portare ad un maggior rischio di sanguinamento e ad un aumentato rischio di rabdomiolisi.
Maggiore
Non specificato Discreta
CARDIOASPIRIN
ORUDIS
549
348
La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione
della mucosa).
Maggiore
Non specificato Discreta
548
CITALOPRAM M.G.
PANTOPRAZOLO M.G.
127
Concurrent use of CITALOPRAM and PANTOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
Maggiore
Nelle 24 ore
CONGESCOR
CORDARONE
Eccellente
548
117
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Nelle 24 ore
COEFFERALGAN
MATRIFEN
Buona
536
130
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
DIFLUCAN
LEVOXACIN
Buona
527
280
La contemporanea assunzione di FLUCONAZOLO e LEVOFLOXACINA può portare ad un aumento del rischio di prolungamento dell’intervallo QT e torsioni di punta
Maggiore
Non specificato Discreta
CITALOPRAM M.G.
SEROQUEL
525
124
Concurrent use of CITALOPRAM and QUETIAPINE may result in increased risk of QT interval prolongation.
CARDIOASPIRIN
TICLOPIDINA M.G.
520
178
Maggiore
Maggiore
Ritardato
Non specificato
Buona
Concurrent use of ASPIRIN and TICLOPIDINE may result in an increased risk of bleeding.
Pag. 6 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Nelle 24 ore
Eccellente
511
97
Concurrent use of SIMVASTATIN and VERAPAMIL may result in increased exposure to simvastatin and an increased risk of myopathy or rhabdomyolysis.
Maggiore
Ritardato
Eccellente
CORDARONE
LANOXIN
494
129
La contemporanea assunzione di DIGOSSINA e AMIODARONE può portare a tossicità da digitalici (nausea, vomito, aritmie cardiache).
Maggiore
Ritardato
COUMADIN
DIURESIX
484
115
La contemporanea assunzione di TORASEMIDE e WARFARIN può determinare un aumento delle concentrazioni plasmatiche di warfarin, una diminuzione della clearance del
warfarin e un elevato INR (tempo internazionale standardizzato di protrombina)
Maggiore
Non specificato Discreta
483
ALIFLUS
ZITROMAX
320
Concurrent use of AZITHROMYCIN and SALMETEROL may result in an increased risk of QT interval prolongation.
Maggiore
COEFFERALGAN
TRANSTEC
474
114
La contemporanea assunzione di ANALGESICI OPPIOIDI e AGONISTI/ANTAGONISTI OPPIOIDI può provocare sintomi da astinenza (crampi addominali, nausea, vomito,
lacrimazione, rinorrea, ansia, irrequietezza, innalzamento della temperatura corporea o piloerezione).
Maggiore
Non specificato Discreta
470
CATAPRESAN TTS2
LOBIVON
89
Concurrent use of CLONIDINE and NEBIVOLOL may result in increased risk of sinus bradycardia; exaggerated clonidine withdrawal response (acute hypertension).
Maggiore
Non specificato Discreta
BISOPROLOLO SAN
CATAPRESAN TTS2
466
85
Concurrent use of BISOPROLOL and CLONIDINE may result in increased risk of sinus bradycardia; exaggerated clonidine withdrawal response (acute hypertension).
Maggiore
Ritardato
Eccellente
COUMADIN
TAVANIC
463
319
Concurrent use of LEVOFLOXACIN and WARFARIN may result in an increased risk of bleeding.
CITALOPRAM DOC
PANTOPRAZOLO DOC G.
ISOPTIN
SIVASTIN
Maggiore
Ritardato
Non specificato
Numero: Assistiti:
Buona
Buona
Discreta
462
122
Concurrent use of CITALOPRAM and PANTOPRAZOLE may result in increased citalopram exposure and risk of QT interval prolongation.
Maggiore
Ritardato
ALDACTONE
ENAPREN
Buona
458
69
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
DELTACORTENE
SEROQUEL
Buona
457
133
450
136
Non specificato
La contemporanea assunzione di QUETIAPINA e GLUCOCORTICOIDI può portare ad una diminuzione delle concentrazioni plasmatiche di quetiapina.
Controindicato Non specificato Discreta
PLASIL
SERENASE
L'utilizzo concomitante di ANTIPSICOTICI e di METOCLOPRAMIDE può aumentare il rischio di sviluppare reazioni exrtrapiramidali o i sintomi della sindrome neurolettica maligna.
Maggiore
Ritardato
Buona
449
GAVISCON ADVANCE
MODURETIC
177
La contemporanea assunzione di POTASSIO e AMILORIDE può determinare iperkaliemia.
LASIX
SOTALOLO HEXAL
131
Maggiore
Non specificato
Buona
447
La contemporanea assunzione di SOTALOLO e DIURETICI può portare ad un aumento del rischio di cardiotossicità (prolungamento dell’intervallo QT, torsioni di punta, arresto
cardiaco).
Maggiore
Non specificato Discreta
447
LEVOXACIN
SERETIDE DISKUS 50/500
245
Concurrent use of LEVOFLOXACIN and SALMETEROL may result in an increased risk of QT interval prolongation.
Pag. 7 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Nelle 24 ore
Buona
Numero: Assistiti:
443
122
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Discreta
CONTRAMAL
TRITTICO
443
118
Concurrent use of TRAMADOL and TRAZODONE may result in increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Maggiore
Non specificato Buona
CARDIOASPIRIN
EUTIMIL
439
145
L'utilizzo concomitante di PAROXETINA e di ANTIAGGREGANTI PIASTRINICI può aumentare il rischio di emorragia.
Maggiore
BRUFEN
CLEXANE T
Non specificato
Buona
438
208
L'utilizzo concomitante di EPARINE A BASSO PESO MOLECOLARE e di FANS può aumentare il rischio di emorragia.
Maggiore
AMIODAR
NORVASC
Nelle 24 ore
Buona
437
85
AMLODIPINA PENSA
SIMVASTATINA PENSA
La contemporanea assunzione di AMIODARONE e BLOCCANTI DEI CANALI DEL CALCIO può portare a bradicardia, blocco atrioventricolare e/o arresto del nodo senoatriale.
Maggiore
Non specificato Buona
435
CERTICAN
SANDIMMUN NEORAL
L'utilizzo concomitante di CICLOSPORINA e di EVEROLIMUS può aumentare il rischio di tossicità da everolimus.
AMIODARONE RATIO
COUMADIN
Maggiore
37
Ritardato
Eccellente
434
177
Nelle 24 ore
Eccellente
431
109
Concurrent use of AMIODARONE and SIMVASTATIN may result in increased exposure to simvastatin and an increased risk of myopathy or rhabdomyolysis.
Maggiore
Nelle 24 ore
Buona
DUROGESIC
MORFINA CL MOLT.
431
174
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
NEXIUM
PLAVIX
427
99
424
100
La contemporanea assunzione di AMIODARONE e WARFARIN può portare ad un aumento del rischio di sanguinamento.
Maggiore
CORDARONE
SIVASTIN
Maggiore
Ritardato
Eccellente
Concurrent use of CLOPIDOGREL and ESOMEPRAZOLE may result in reduction in clinical efficacy of clopidogrel and increased risk for thrombosis.
Maggiore
Nelle 24 ore
Buona
AMIODARONE SANDOZ
NORVASC
La contemporanea assunzione di AMIODARONE e BLOCCANTI DEI CANALI DEL CALCIO può portare a bradicardia, blocco atrioventricolare e/o arresto del nodo senoatriale.
Maggiore
Non specificato Buona
420
CLEXANE
TORADOL
213
L'utilizzo concomitante di EPARINE A BASSO PESO MOLECOLARE e di FANS può aumentare il rischio di emorragia.
Maggiore
CLEXANE
ZOLOFT
Ritardato
Buona
418
169
La contemporanea assunzione di SERTRALINA e ANTICOAGULANTI può determinare un maggior rischio di sanguinamento.
Maggiore
EFFENTORA
OXYCONTIN
Nelle 24 ore
Buona
418
51
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
INEGY
NORVASC
Nelle 24 ore
Buona
416
96
412
250
Maggiore
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Non specificato Discreta
ARTROSILENE
CARDIOASPIRIN
Pag. 8 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Numero: Assistiti:
La contemporanea assunzione di ASPIRINA e KETOPROFENE può portare ad un aumento del rischio di seri effetti avversi gastrointestinali (ulcera, sanguinamento, perforazione
della mucosa).
Maggiore
Nelle 24 ore
Eccellente
410
AMIODAR
BISOPROLOLO SAN
105
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Ritardato
MODURETIC
ZESTRIL
Buona
409
81
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
ISOPTIN
TOTALIP
Discreta
407
85
Concurrent use of ATORVASTATIN and VERAPAMIL may result in increased exposure to atorvastatin and an increased risk of myopathy or rhabdomyolysis.
Maggiore
Non specificato Discreta
BACTRIM
DIFLUCAN
402
178
Non specificato
La contemporanea assunzione di COTRIMOXAZOLO e FLUCONAZOLO può portare ad un aumento del rischio di cardiotossicità (intervallo QT prolungato, torsioni di punta, arresto
cardiaco).
Maggiore
Non specificato Discreta
401
DUROGESIC
TRITTICO
62
Concurrent use of FENTANYL and TRAZODONE may result in increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Maggiore
Ritardato
Buona
MODURETIC
RAMIPRIL DOC G.
401
113
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
ALLOPURINOLO TEVA
ENAPREN
398
127
Nelle 24 ore
Discreta
La contemporanea assunzione di ALLOPURINOLO e ENALAPRIL può portare a reazioni di ipersensibilità (sindrome di Stevens-Johnson, eruzioni cutanee, spasmo coronarico
anafilattico).
Maggiore
Non specificato Buona
398
CARDIOASPIRIN
VENLAFAXINA MG
91
La contemporanea assunzione di VENLAFAXINA e AGENTI ANTIAGGREGANTI può portare ad un maggior rischio di sanguinamento.
Maggiore
Nelle 24 ore
ORAMORPH
OXYCONTIN
Buona
398
120
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
NORVASC
ZOCOR
Buona
396
78
393
231
Maggiore
Nelle 24 ore
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Controindicato Nelle 24 ore
Discreta
BRUFEN
TORADOL
La contemporanea assunzione di KETOROLAC e AGENTI ANTIINFIAMMATORI NON STEROIDEI può portare ad effetti avversi gastrointestinali seri (ulcere peptiche, emorragia e/o
perforazione gastrointestinale)
Maggiore
Ritardato
Buona
385
ALDACTONE
RAMIPRIL M.G.
77
La contemporanea assunzione di DIURETICI RISPARMIATORI DI POTASSIO e ACE-INIBITORI può causare iperkaliemia.
Maggiore
Non specificato Discreta
381
DEPAKIN
TRITTICO
83
Concurrent use of TRAZODONE and VALPROIC ACID may result in increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes).
Maggiore
Non specificato Discreta
380
FOSTER
LEVOXACIN
258
Concurrent use of FORMOTEROL and QT PROLONGING DRUGS may result in increased risk of ventricular arrhythmias.
Pag. 9 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.
Bergamo 2011/2012 - IF per farmaco
Assititi: tutti
Periodo : 01.10.2011 - 30.09.2012. Interaz. su 30 gg: Contr., Magg
Farmaci
Severità:
Insorgenza:
Doc.:
Maggiore
Nelle 24 ore
Eccellente
376
63
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Non specificato
LEVOXACIN
ZITROMAX
Discreta
376
288
Concurrent use of AZITHROMYCIN and LEVOFLOXACIN may result in an increased risk of QT interval prolongation.
Maggiore
NORVASC
VYTORIN
Buona
374
77
373
58
AMIODAR
DILATREND
Nelle 24 ore
Concurrent use of AMLODIPINE and SIMVASTATIN may result in increased simvastatin exposure and increased risk of myopathy, including rhabdomyolysis.
Maggiore
Nelle 24 ore
Buona
ADALAT CRONO
CORDARONE
Numero: Assistiti:
La contemporanea assunzione di AMIODARONE e BLOCCANTI DEI CANALI DEL CALCIO può portare a bradicardia, blocco atrioventricolare e/o arresto del nodo senoatriale.
Maggiore
Ritardato
Buona
370
COUMADIN
ZOLOFT
131
La contemporanea assunzione di SERTRALINA e ANTICOAGULANTI può determinare un maggior rischio di sanguinamento.
Maggiore
DEPALGOS
TACHIDOL
Nelle 24 ore
Buona
368
167
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
LUCEN
PLAVIX
Ritardato
Eccellente
362
89
Concurrent use of CLOPIDOGREL and ESOMEPRAZOLE may result in reduction in clinical efficacy of clopidogrel and increased risk for thrombosis.
Maggiore
Non specificato Discreta
CLEXANE
PLAVIX
Maggiore
361
162
L'utilizzo concomitante di CLOPIDOGREL ed ANTICOAGULANTI può provocare un aumentato rischio di emorragia.
Maggiore
HALDOL
LARGACTIL
361
78
La contemporanea assunzione di ANTIPSICOTICI e FENOTIAZINE può portare ad un aumento del rischio di cardiotossicità (intervallo QT prolungato, torsioni di punta, arresto
cardiaco).
359
Maggiore
Non specificato Buona
HALDOL
SEROQUEL
95
La contemporanea assunzione di QUETIAPINA e ALOPERIDOLO può portare ad un aumento del rischio di cardiotossicità (intervallo QT prolungato, torsioni di punta, arresto
cardiaco).
Maggiore
Nelle 24 ore
Eccellente
353
AMIODARONE RATIO
BISOPROLOLO SAN
126
La contemporanea assunzione di AMIODARONE e BLOCCANTI BETA-ADRENERGICI può portare ad ipotensione, bradicardia o arresto cardiaco.
Maggiore
Non specificato
CLEXANE
OKI
Buona
353
202
L'utilizzo concomitante di EPARINE A BASSO PESO MOLECOLARE e di FANS può aumentare il rischio di emorragia.
Maggiore
AMLODIPINA DOC G.
PLAVIX
Eccellente
348
125
Concurrent use of AMLODIPINE and CLOPIDOGREL may result in decreased antiplatelet effect and increased risk of thrombotic events.
Maggiore
Non specificato
LYRICA
TORADOL
Discreta
347
164
L'utilizzo concomitante di KETOROLAC e ANTICONVULSIVANTI può ridurre l'effetto anticonvulsivante.
OXYCONTIN
TACHIDOL
Buona
344
131
Maggiore
Non specificato
Non specificato
Nelle 24 ore
Discreta
L'utilizzo concomitante di farmaci analgesici oppioidi può sfociare in una depressione respiratoria
Pag. 10 di 1.539
Le interazioni segnalate sono ottenute interrogando la banca dati MICROMEDEX DRUG-REAX® della THOMSON REUTERS.